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RADIOLOGICAL, PHYSIOLOGICAL AND PSYCHOSOCIAL VARIABLES 
BEFORE AND AFTER UTERINE ARTERY EMBOLIZATION FOR FIBROIDS. 
Elizabeth Kagan Arleo, Michael G. Tal, and Robin M. Masheb. Vascular and 
Interventional Radiology Division, Department of Diagnostic Radiology, and Department 
of Psychiatry, Yale University School of Medicine, New Haven, CT. 
Purpose: To investigate MRI-determined uterine and fibroid size and location, and 
fibroid-related symptoms, including quality of life and sexual function, in women with 
symptomatic fibroids before and after uterine artery embolization (UAE), as well as 
changing trends in gynecologists’ opinion of the procedure. 
Methods: Fifty-two women underwent pelvic MRI within four weeks of and six months 
post-procedure, from which uterine and fibroid size and location were noted. Women also 
completed a self-report questionnaire within four weeks before and one to six months 
after the procedure; the questionnaire investigated the frequency of fibroid-related 
symptoms, as well as quality of life and sexual function via the Short Form-36 (SF-36) 
and Female Sexual Function Index (FSFI). In addition, over a four year period, forty-two 
women completed a telephone survey in which each was asked about her gynecologist’s 
initial opinion of UAE and about who initiated discussion of UAE. 
Results: At baseline, women with symptomatic fibroids had worse quality of life and 
sexual function scores than healthy controls (p<.05). Pre-UAE, MRI-determined uterine 
and fibroid volumes were significantly correlated with urinary frequency/urgency (p<.02) 

and some aspects of quality of life (p<.04), but not with other fibroid-related symptoms 
or sexual function. No significant differences with respect to fibroid-related symptoms 
were found between patients with or without subserosal or submucosal fibroids. After 
UAE, uterine and fibroid volumes significantly decreased (pc.03), as did urinary and pain 
symptoms (pc.003), as well as several aspects of quality of life (pc.005). In addition, 
more gynecologists had a favorable opinion of and were offering UAE than two years 
previously, (pc.05). 
Conclusions: Women with symptomatic fibroids had impaired quality of life and sexual 
function, several aspects of which were correlated with uterine and fibroid volumes. 
Treatment with UAE, increasingly accepted by gynecologists, can significantly reduce 
uterine and fibroid volume and improve fibroid-related symptoms. 
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INTRODUCTION 
“The available evidence on the management of uterine leiomyomata is of poor 
quality. Patients, clinicians, and policy makers do not have the data needed to 
make informed decisions about appropriate treatment. Given the prevalence of 
this condition and its substantial impact on women’s lives, obtaining these data 
should be a high research priority.” 
— Myers et ai, 2002 (1) 
Uterine fibroids - also known as myoma, leiomyoma, and leiomyomata - are one 
of the most common conditions affecting women of reproductive age, with prevalence 
ranging from 20-77% (2). Thirty-five to fifty percent of women with fibroids are 
symptomatic, experiencing menorrhagia, pain (dysmenorrhea, dyspareunia), pressure- 
related symptoms (urinary frequency/urgency, constipation, bloating) and/or reproductive 
difficulties (infertility, miscarriage) (3). These benign tumors, which arise from the 
smooth muscle cells of the uterus, typically regress with menopausal decrease in steroid 
hormones. However, women taking hormone replacement therapy may continue to 
experience fibroid-related symptoms. The diagnosis of fibroids is made by history, 
pelvic/abdominal examination, and pelvic ultrasound or Magnetic Resonance Imaging 
(MRI). 
Despite the prevalence of uterine fibroids and their considerable effect on 
women’s lives, and despite cell physiologic advances including the identification of 145 
genes involved in fibroid growth and development (4), a recent systematic literature 
review concluded that there is little high-quality evidence with which to answer basic 
questions about fibroid treatment strategies (1). Therefore, the purpose of this research 
was to use quantitative MRI data and validated instruments to establish baseline 
radiological, physiological and psychosocial characteristics of premenopausal women 
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with symptomatic uterine fibroids and to follow these variables after treatment with 
uterine artery embolization (UAE), a relatively new procedure in the fibroid treatment 
armamentarium. 
Fibroid-related symptoms 
Although fibroids can cause a number of symptoms, exactly how they do so is 
unclear. One theory about the cause of bleeding symptoms is that fibroids may increase 
the number, but impede the function, of uterine blood vessels; another is that the presence 
of fibroids may impede the ability of the uterus to contract, thus causing inefficient 
expulsion of menstrual material or impairing the ability of uterine arteries to clamp down 
(5). The mass effect of fibroids (i.e., compressing the urinary bladder) is widely believed 
to be the mechanism by which fibroids cause urinary symptoms. However, anecdotal 
evidence from post-UAE patients that improvement in urinary symptoms precedes 
significant shrinkage in fibroid volume suggests that other mechanisms may play a role 
as well (6). The etiology of fibroid-related pain, including dysmenorrhea and 
dyspareunia, may be related to mass effect as well, or in some cases may be a side effect 
of attempted medical treatment (e.g., GnRH analogs, which may alter normal serum 
estrogen levels, can cause vaginal epithelial atrophy, decreased lubrication, and thus 
sexual pain). 
In addition, fibroid-related symptoms are typically thought to be a function of 
size, location, and number of fibroids. In terms of size, the risk of fibroid-related 
symptoms, especially bleeding, is thought to increase with leiomyoma volume (7). In 
terms of location, menorrhagia has been attributed to intramural and submucosal fibroids. 
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whereas pelvic pain or pressure is more often attributed to intramural or subserosal 
fibroids (8). In terms of number of fibroids, the impact appears to be chronically 
undocumented, given that a recent systematic review of the literature on surgical and 
non-surgical management of fibroids found that 70% of studies on invasive treatments 
did not provide information on the number of leiomyomata (1). 
The decision to treat symptomatic fibroids often is made based on uterine or 
fibroid size, or fibroid location, despite the fact that the relationship between these 
variables is not well established. For example, whereas it is known that the severity of 
endometriosis-related symptoms does not necessarily correlate with the amount (3) but 
does correlate with the location of endometriosis (9), it is not known whether the severity 
of fibroid-related symptoms necessarily correlates with uterine or fibroid size, or fibroid 
location within the uterus. This information is clinically relevant for the evidence-based 
treatment decision-making. The postulated association between submucosal fibroids and 
heavy bleeding (7), widely accepted clinically, often leads to hysteroscopic resection of 
fibroids located submucosally. Alternatively, a patient undergoing myomectomy or 
uterine artery embolization (UAE) may be counseled on the extent to which she may 
expect her fibroid-related symptoms to improve based on the location of her fibroids (10). 
The first aim of this research, therefore, was to investigate the relationship between 
baseline MRI-determined total uterine volume, largest fibroid volume and fibroid 
location, and fibroid-related symptoms in premenopausal women with symptomatic 
uterine fibroids. 
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Quality of life and sexual function 
The increased awareness of subjective well-being as a critical factor in health 
outcomes research has led to a proliferation of studies utilizing health-related quality-of- 
life (HRQOL) measures for assessing subjective well-being. HRQOL measures fall into 
two categories: disease/disorder-specific, or generic, such as the Medical Outcomes 
Study Short Form-36 Health Survey (SF-36) (11), a well-established generic HRQOL 
measure. However, to date, minimal data exists characterizing the quality of life, 
including sexual function, of women with leiomyomata by either method. Spies et al (12) 
developed a fibroid-specific version of the SF-36 and found that women with fibroids 
experienced lower health-related quality of life, as well as diminished sexual function, 
than normal controls, but to our knowledge, no generic HRQOL measure has been 
applied to establish baseline characteristics of women with fibroids alone. 
A number of theories have been proposed to explain how fibroids cause sexual 
dysfunction. The mass effect theory suggests that uterine fibroids can have a direct 
mechanical influence on women’s sexual function by making it difficult for the uterus to 
elevate and enlarge during arousal and contract during orgasm (13). It has also been 
hypothesized that fibroid-related vascular changes can have a direct effect on women’s 
sexual function as well (i.e., vessels feeding fibroids “stealing” blood from pelvic organs) 
(14). In a paper on an animal model of vasculogenic female sexual dysfunction, 
Goldstein et al (15) reported that “vaginal engorgement and clitoral erectile insufficiency 
syndromes...exist when during sexual stimulation abnormal arterial circulation into the 
vagina or clitoris, usually from atherosclerotic vascular disease, interferes with normal 
vascular physiologic processes. Clinical symptoms may include delayed vaginal 
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engorgement, diminished vaginal lubrication, pain or discomfort with intercourse, 
diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation 
or diminished clitoral orgasm.” If fibroid neovascularization creates an abnormal arterial 
circulation into the vagina or clitoris, and/or a state of relative chronic ischemia of the 
pelvic organs, then this may be another possible mechanism by which fibroids cause 
sexual dysfunction. 
Fibroids may also have an indirect biological influence on sexual function. 
Menorrhagia secondary to fibroids can cause iron-deficiency anemia, which may 
contribute to fatigue and thus negatively affect sexual desire. In addition, the side effects 
of medical therapies for fibroids, such as GnRH analogs, may alter normal serum 
estrogen levels, which can cause vaginal epithelial atrophy, decreased lubrication, and 
thus sexual pain. Fibroids may have an indirect psychological influence on sexual 
function as well. Abdominal enlargement secondary to fibroids may lead to detrimental 
changes in body- and self-image, feelings of being less attractive or sexy, and depression. 
Women may fear being rejected sexually, or conversely, worries about bulk, bladder and 
bowel dysfunction, or vaginal bleeding during intercourse may cause them to reject 
sexual activity. Reports from focus groups by Spies et al (12) corroborate both these 
possibilities: “Dissatisfaction with one’s appearance also had an impact on sexual 
function as some women in the focus groups “did not feel attractive”...[In addition, 
women stated that they ] avoided sexual relations because of menorrhagia related to their 
leiomyomata.” Another hypothesis is that dyspareunia might lead a woman with fibroids 
to think that she has to endure pain with intercourse to satisfy her partner, or alternatively 
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may lead to avoidance of sexual activity. Failure to express these concerns to a partner 
may then cause difficulties in interpersonal relationships. 
Given that fibroids can have profound direct and indirect biological and 
psychological influences on sexual function, and quality of life, the second aim of this 
research was to characterize the quality of life and sexual function of premenopausal 
women seeking interventional treatment for symptomatic uterine fibroids. 
Fibroid treatment options 
Historically, the treatment of fibroids has been surgical, with surgical treatment 
options including hysterectomy and myomectomy, and more recently, transvaginal 
resection of fibroids (16), endometrial ablation (17), laparoscopic-directed thermal 
coagulation (18), laser coagulation (19), cryotherapy (20), and MRI-guided focused 
ultrasound surgery (21). Hysterectomy is currently the most common surgical treatment 
for women with uterine fibroids, and fibroids are the number one discharge diagnosis for 
hysterectomy: of the estimated 600,000 hysterectomies performed annually in the United 
States, 40% are performed for fibroids (22). Myomectomy is the second most common 
surgical treatment for women with fibroids: an estimated 35,000 myomectomies are 
performed annually, including hysteroscopic myomectomies (to remove submucosal 
fibroids), laparoscopic myomectomies (to remove fibroids located serosally), and 
abdominal myomectomy (for fibroids in all locations) (23). However, since neither 
hysterectomy nor myomectomy is an ideal solution, nonsurgical treatments have been in 
high demand. Medical treatment options include GnRH analogs (24), gestrione (25), and 
low-dose mifepristone (26). However, many women are unresponsive to such medical 
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treatments or experience symptom recurrence after cessation of treatment (27). Given 
these limitations, UAE - first described as a treatment for fibroids by Ravina et al in 
1995 (28), but utilized for twenty years preceding for the treatment of post-partum 
hemorrhage - has been increasing in popularity. To date, over 30.000 UAEs have been 
performed worldwide to treat fibroids (29). 
Hysterectomy, myomectomy, and uterine artery embolization each have their 
advantages and disadvantages. In terms of overall success rates - defined as marked or 
complete resolution of fibroid-related symptoms, requiring no further treatment - there 
are notable differences: hysterectomy offers the advantage of complete cure by virtue of 
removing the fibroid uterus, in contrast to overall success rates of 75% for myomectomy 
(30) and 85-94% for UAE (31). Hysterectomy, however, is a major surgical procedure, 
involves several days of hospitalization and up to six weeks of convalescence, and results 
in permanent loss of the uterus and fertility. While myomectomy preserves the uterus, it 
is still major abdominal surgery associated with hospital and recovery times similar to 
hysterectomy, and with the potential for formation of painful, fertility-impairing 
abdominal adhesions. In contrast, UAE preserves the uterus, in the context of shorter 
hospital (<24 hours) and recovery times (1-2 weeks). Using ACOG’s (American College 
of Obstetricians/Gynecologists) definitions for perioperative complications, the overall 
morbidity of UAE has been reported to be 5%, compared to an overall morbidity of 
38.6% for myomectomies and 40.1% for hysterectomies (31). Furthermore, life- 
threatening events - defined as cardiopulmonary arrest, resuscitation, unplanned 
admission to an intensive care unit, or death - have been reported to occur in 0.5% of 
UAEs, in contrast to 1.5% of myomectomies and 1.0% of hysterectomies (31). However, 
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some reports have found that pregnancy after UAE may be complicated by higher rates of 
C-section, preterm labor, malpresentation, spontaneous abortion, and post-partum 
hemorrhage than normally occurs in the general population, which in part might be due to 
residual fibroids (32). On the other hand, Oman et al, who studied the long-term sequelae 
of pelvic embolization for postpartum hemorrhage on fertility, found that all patients who 
desired to get pregnant were able to do so and experienced uncomplicated deliveries in 
the years after their embolization (33). Case series on pregnancy after myomectomy 
report rates of premature delivery and other complications to be similar to rates for the 
general population, however, the need for C-section necessarily increases if the uterine 
cavity was substantially entered during myomectomy (34). 
The increased interest in UAE as a minimally invasive treatment option for 
fibroids has led to studies primarily assessing volume reduction and symptom relief. 
Most have used ultrasound, and quality of life and sexual function have been less well 
examined. For example, there have been case reports about sexual dysfunction after UAE 
(35), but no published studies prospectively assessing the effect of UAE on sexual 
function using validated measures. Therefore, the third aim of this research was to 
reevaluate total uterine volume and largest fibroid volume, as well as fibroid-related 
symptoms including quality of life and sexual function, after treatment with UAE using 
quantitative MRI data and two validated instruments. 
Finally, given that gynecologists have traditionally been the providers of 
treatment for uterine fibroids (i.e., performing hysterectomy, myomectomy), the fourth 
aim of this research was to investigate patients’ perceptions of their gynecologists’ 
opinion of UAE. 
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Statement of purpose 
In summary, the aim of this thesis was to test the following four hypotheses: 
1. There is a relationship between baseline MRI-determined uterine and fibroid size 
and fibroid location within the uterus, and fibroid-related symptoms. 
2. Women with symptomatic uterine fibroids have worse quality of life and sexual 
function than healthy women controls. 
3. Following treatment with UAE, uterine and fibroid size decrease, and fibroid- 
related symptoms improve. 
4. More gynecologists are expressing a favorable opinion of UAE and are offering 
UAE than two years earlier. 
It is relevant to test these hypotheses given the prevalence of fibroids and the increasing 
role of radiology in fibroid diagnosis and treatment. The practical benefit is that data 
from this research will provide information for physicians and patients engaged in the 
fibroid-treatment decision-making process. 
METHODS 
Study design and subjects 
The patient sample, prospectively accrued, consisted of premenopausal women 
undergoing UAE in the Department of Diagnostic Radiology, Vascular and 
Interventional Radiology Division, at Yale-New Haven Hospital. Patients were self- 
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referred or referred by gynecologists to the department for treatment. Exclusion criteria 
for the study were malignancy and postmenopausal status. Eligibility was not restricted 
by age, uterine or fibroid size, sexual orientation, or desire for fertility preservation. One- 
hundred and fifteen women had UAE performed by one of two hospital-based 
Interventional Radiologists (Michael G. Tal, MD, and Jeffrey Poliak, MD) from June 
2001 through December 2003, and all women were offered the opportunity to participate 
in the study by either the Interventional Radiologist or his nurse practitioner. Fifty-two 
(45%) of these women chose to participate and completed the questionnaire prior to 
treatment with UAE. The same questionnaire was mailed (by the author) to these 
participating women after treatment with UAE, and thirty-seven (71%) returned follow¬ 
up questionnaires one to six months after the procedure. Hospital review board approval 
and patient informed consent were obtained. 
Imaging 
Following hospital UAE imaging protocol, women underwent pelvic MRI within 
four weeks of UAE and six months post-procedure. MRI was performed in the 
department utilizing a 1.5T scanner (General Electric, Signa, Milwaukee, WI) with a 
pelvic phased array coil. Following a gradient echo localizer sequence, sagital STIR, 
axial TI weighted SE, and axial and coronal FSE were obtained. Pre- and post¬ 
gadolinium scans were obtained in the sagital plane to assess for myoma enhancement. 
The presence of submucosal fibroids, intramural fibroids with a submucosal component, 
intramural fibroids, subserosal fibroids with an intramural component, and subserosal 
fibroids were noted at baseline. Uterine dimensions were obtained from an axial image 
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via electronic cursor measurements of the mid corpus width and AP dimensions, and 
length was measured from a sagital image from the top of the fundus (or fundal myoma if 
present) to the external os. Largest myoma diameter was obtained via cursor 
measurement from axial and sagital images. Total uterine volume was calculated using 
the equation for the volume of an ellipse |CC x AP x transverse x .52], and largest fibroid 
volume was calculated using the equation for the volume of a sphere [4/3jc x (largest 
myoma diameter/2)3]. MRI scans were read by residents and confirmed by attendings. 
Volume calculations were double-checked by the author. 
Questionnaires 
Demographic and fibroid-related questionnaires were created by Dr. Tal and Robin 
M. Masheb, PhD. In terms of demographic and clinical information, each patient was 
asked about her age, race, education, marital status, employment, and primary reason for 
seeking treatment. To assess fibroid-related symptoms, each patient was asked to rate the 
frequency of urinary symptoms (frequency/urgency, incontinence), pain (pelvic, 
abdominal, back), bleeding and bowel symptoms (constipation, diarrhea) that she 
experienced in the month prior to the survey on a scale of 0 (not at all), 1 (about one- 
fourth of the days in the past month), 2 (about one-half of the days in the past month), 3 
(about three-fourths of the days in the past month) to 4 (every day in the past month). 
In addition, each patient was asked to complete the following health-related quality of 
life and sexual function instruments, respectively: 
1. Medical Outcomes Study Form Short-Form 36 (SF-36) Health Survey (1992) 
(36): The SF-36 is a 36-item, state-of-the-art, self-report instrument to assess 
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health-related quality of life. The SF-36 has well-established reliability and 
validity, and was developed for use in the Medical Outcomes Study (37, 38). The 
scale includes eight domains known to be most directly affected by disease and 
treatment: physical functioning, social functioning, physical role limitation, 
emotional role limitation, bodily pain, general health, mental health, and vitality. 
SF-36 raw scale scores are transformed to t-scores (39). Higher scores reflect 
better functioning for all subscales. 
2. Female Sexual Function Index (FSFI) (2000) (40): The 19-item FSFI has six 
subscales — desire, arousal, lubrication, orgasm, satisfaction, and pain — as well 
as an overall score. The questionnaire was developed as a multidimensional self- 
report instrument for assessing the key domains of sexual function in women. 
High test-retest reliability (r=0.79 to 0.86) and internal consistency (Cronbach’s 
alpha values greater than and equal to 0.82), as well as construct and divergent 
validity have been reported. Individuals are asked questions such as how difficult 
it was to become lubricated (“wet”) during sexual activity or intercourse over the 
past four weeks on a scale from extremely difficult, or impossible, to not difficult. 
Higher scores reflect better sexual functioning. 
Uterine artery embolization 
Bilateral selective uterine artery catheterization was performed with the use of 
fluoroscopic guidance. The catheter tips were placed within the transverse portion of the 
uterine arteries. Bilateral angiography was performed in order to identify the arterial 
anatomy and the branches feeding the fibroids. Five hundred to 710 micron polyvinyl 
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alcohol particles were then injected into each uterine artery until stasis or near stasis was 
achieved. Following embolization, a final arteriogram was obtained. Figure 1 shows pre- 
and post-embolization arteriograms for vasculature of a fibroid uterus. After the 
procedure, each patient was admitted overnight to the Interventional Radiology service 
for post-procedural pain management as needed. 
Figure 1. a) Pre-embolization arteriogram of pelvic vasculature of a fibroid uterus, b) 
Post-embolization arteriogram of pelvic vasculature of a fibroid uterus, 
a) b) 
Telephone survey 
In order to investigate trends in gynecologists’ opinions of UAE for fibroids, a 
telephone study was initiated in August 1998 to assess patients’ perceptions of their 
gynecologists’ opinion of the procedure. The surveys were administered to women 
undergoing UAE as above from August 1998 to July 2000 (by Dr. Tal) and from July 
2000 to April 2002 (by the author). Twenty-one patients completed the survey during 
each time frame. Women were contacted chronologically, beginning with the first women 
to have UAE in each of the respective time frames; participating women represent the 
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first twenty-one women to be reached by telephone in each group. Each participant was 
asked to rate her perception of her gynecologist’s initial opinion of UAE before the 
procedure on a scale from 1 (strongly opposed) to 6 (very favorable) or 7 (unaware of the 
procedure); whether the gynecologist offered UAE as a treatment option; whether she or 
the gynecologist initiated discussion of UAE; and whether she continued to see the same 
gynecologist after the procedure. In the second time frame, each participant was also 
asked whether she had Internet access at home and whether she used the Internet to learn 
about UAE. 
Analysis 
Data was analyzed using SPSS, version 10.0 (SPSS Inc, Chicago, IL) by the 
author and Dr. Masheb. Frequency and percentages were calculated for categorical 
variables, and means and standard deviations were calculated for continuous variables. 
Pearson product moment correlation coefficients were used to examine relationships 
among variables. Chi squares, t-tests, and ANOVAs were used the determine between- 
group differences. 
Baseline quality of life and sexual function data were further analyzed using 
effect sizes to compare the present sample with normative samples. Effect sizes were 
determined by calculating the difference in scale scores between the UAE sample and the 
control samples, and dividing by the average deviation of the two samples. Effect sizes 
of 0.20, 0.50, and 0.80 or greater were considered small, medium, and large, respectively 
(41), and student t tests were calculated to determine the significance of the effect sizes. 
The control samples included a representative sample of the female general population 
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from the validation studies of the SF-36 (39) and a representative sample of healthy 
women from the original validation study of the FSF1 (40). 
Data from the telephone survey assessing changing trends in gynecologists’ 
opinion of UAE were analyzed using Statcalc 1.1 (StatCalc Software, Etext.net publisher, 
Venice, CA). Frequency and percentiles were calculated for categorical variables. All 
reported p values were based on Fisher exact tests. 
RESULTS 
[N.B. The variation in N is a function of patients failing to answer all items on the 
questionnaires, and MRls and MR1 reports missing from the hospital file room and 
1DXRAD, the hospital computer radiology report system, respectively.] 
Baseline Pre-UAE Data 
The demographic and clinical characteristics of the participating women with 
symptomatic fibroids seeking UAE are displayed in Table 1. The mean patient age was 
45 years (range 33-56). The majority (54%) of women were Caucasian; 40% were 
African-American, and 6% were Asian. Most women (59%) were highly educated, either 
holding a four-year college degree or a graduate degree or professional training. Women 
were more likely to be married or cohabiting or with a significant other (60%) than 
divorced, separated, widowed, or never married (40%). Women were mostly working 
full-time (78%), but 8% were unemployed. 
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Patients were asked about their primary reason for seeking treatment for their 
fibroids via a fill-in-the-blank question format. The majority of patients responded with 
more than one reason. Responses were then coded by the author into the following six 
categories: bleeding, pain, bulk, urinary, bowel symptoms, and dyspareunia. The most 
common reasons patients reported were bleeding (53%) and pain (51%). In addition, 31% 
self-reported bulk, 22% self-reported urinary symptoms, 4% self-reported bowel 
symptoms, and 4% reported dyspareunia as the primary reason for seeking fibroid 
treatment. 
Table 1. Demographic and clinical characteristics of women with symptomatic fibroids seeking UAE 
Mean SD 
Age (N=52) 45.04 6.27 
Total uterine volume (N=46) 841.69 cc 595.11 cc 
Largest fibroid volume (N=46) 347.80 cc 352.47 cc 
N % 
Race (N=52) 
• Caucasian 28 53.8 
• African American 21 40.4 
• Asian 3 5.8 
Education (N=51) 
• Less than high school 1 2.0 
graduate 
• High school graduate 7 13.7 
• Partial college or 13 25.5 
specialized training 
• 4-year college graduate 14 27.5 
• Graduate 16 31.4 
degree/professional 
training 
Marital status (N=52) 
• Never married 9 17.3 
• Married or cohabiting 28 53.8 
• Significant other 3 5.8 
• Divorced/separates 11 21.2 
• Widowed 1 1.9 
Employment status (N=49) 
• Working full-time (over 38 77.6 
30 hrs/wk) 
• Working part-time (less 6 12.2 
than 30 hrs/wk) 
• Unemployed 4 8.2 
• Student 1 2.0 
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Table 1 (continued) 
Primary reasons for seeking 
treatment (N=49)* 
• Urinary 11 22.4 
• Pain 25 51.0 
• Bleeding 26 53.1 
• Bowel 2 4.1 
• Bulk 15 30.6 
• Dyspareunia 2 4.1 
* Note: Does not total to 100% because many women reported more than one primary reason for treatment. 
The mean total uterine volume pre-UAE was 842 cc (range 91-2870 cc) and the 
mean largest fibroid volume pre-UAE was 348 cc (range 1.44-1837.85 cc). Overall, 91% 
of women had intramural fibroids, 54% had subserosal fibroids, 30% had submucosal 
fibroids, 26% had intramural fibroids with a submucosal component, and 5% had 
subserosal fibroids with an intramural component (Table 2). The majority of women 
(74%) had fibroids in more than one location. Of the 26% with fibroids in one location, 
the most frequent location was intramural (82%). 
Table 2. Fibroid locations in women with symptomatic fibroids seeking UAE (N=43) 
Present Absent 
Location N % N % 
Intramural 39 90.7 4 9.3 
Subserosal 23 53.5 20 46.5 
Submucosal 13 30.2 30 69.8 
Intramural with 
submucosal 
component 
11 25.6 32 74.4 
Subserosal with 
intramural 
component 
2 4.7 41 95.3 
In terms of fibroid-related symptoms (Table 3), most women reported urinary 
frequency/urgency (81%), as well as pain (pelvic, abdominal, back) (81%) at least one- 
fourth of the days or more in the month prior to the survey. In addition, 56% of women 
reported bowel symptoms (constipation, diarrhea), and 33% reported bleeding at least 
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one-fourth of the days or more in the month prior to the survey. Furthermore, 48% of 
women reported urinary symptoms every day in the month prior to the survey. 
Table 3. Frequency of Fibroid-related symptoms in women with symptomatic fibroids seeking UAE (N=52) 
1/4 of days in 1/2 of days in 3/4 of days in Everyday in Totals: 1/4 of 
Symptoms Not at all past month past month past month past month days or more 
N % N % N % N % N % N % 
Urinary 10 19.2 8 15.4 6 11.5 3 5.8 25 48.1 42 80.8 
Pain 10 19.2 15 28.8 9 17.3 9 17.3 9 17.3 42 80.8 
Bleeding 35 67.3 6 11.5 5 9.6 2 3.8 4 7.7 17 32.7 
Bowel 23 44.2 13 25.0 10 19.2 3 5.8 3 5.8 29 55.8 
Table 4 contains the SF-36 means and standard deviations at baseline for the 
cohort of women with symptomatic fibroids pre-UAE and for the representative sample 
of the female general population from the validation studies of the SF-36 (39). In five of 
the eight quality of life subscales — including physical role, bodily pain, general health, 
vitality, and social functioning — the mean scores of women with symptomatic fibroids 
were significantly different than the mean scores of the female general population at the 
p<.05 level. In four of the five significant subscales, women with symptomatic fibroids 
reported worse health-related quality of life than the female general population, with 
effect sizes ranging from small to moderate. However, in terms of the general health 
subscale, women with fibroids reported better health-related quality of life than the 
female general population. 
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Table 4. Means, standard deviations, effect sizes, and paired t-tests for the SF-36 in women with 
symptomatic fibroids and U.S. female norms* 
Women with U.S. female norms* 
fibroids (N=46) (N=1412) Effect size** 
SF-36 Mean SD Mean SD Quanti¬ 
tative 
Quali- 
Tative 
t P 
Physical 76.9 25.0 81.5 24.6 -0.19 ns -1.24 ns 
functioning 
Physical role 65.7 39.1 77.8 36.2 -0.32 Small -2.07 <. 025 
Bodily pain 64.4 25.6 73.6 24.3 -0.37 Small- 
moderate 
-2.40 <. 01 
General 80.0 14.1 70.6 21.5 0.53 Moderate 4.38 <. 005 
health 
Vitality 48.3 25.3 58.4 21.5 -0.43 Small 
moderate 
-2.68 <. 005 
Social 75.2 24.8 81.5 23.7 -0.26 Small -1.71 <. 05 
functioning 
Emotional 74.8 38.1 79.5 34.4 -0.13 ns -0.82 ns 
role 
Mental health 69.6 20.0 73.3 18.7 -0.19 ns -1.23 ns 
* Sample from the National Survey of Functional Health Status (Ware et al., 1993) (39). 
** Effect sizes of 0.20, 0.50, and 0.80 or greater are considered small, moderate and large, respectively 
(Kazis et al., 1989) (41). 
ns = not significant. 
Higher scores reflect better health-related quality of life. 
Table 5 contains the FSF1 means and standard deviations at baseline for the 
cohort of women with symptomatic fibroids pre-UAE and for the representative sample 
of healthy women from the original validation study of the FSF1 (40). In all sexual 
function subscales - including desire, arousal, lubrication, orgasm, satisfaction and pain - 
- and the overall score, the mean scores of women with symptomatic fibroids were 
significantly different than the mean scores of healthy women controls at the p<.005 
level. Women with symptomatic fibroids reported worse sexual function than healthy 
women controls, with effect sizes ranging from small to moderate. 
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Table 5. Means, standard deviations, effect sizes, and paired t-tests for the FSF1 in women with 
symptomatic fibroids and healthy women without sexual dysfunction* 
Women with Healthy women 
Fibroids w/o sexual dys- 
(N= :46) function (N= 131)* Effect size * * 
FSFI Mean SD Mean SD Quanti¬ 
tative 
Quali- 
Tative 
t P 
Desire 5.7 2.0 6.9 2.4 -.54 Moderate -3.56 <. 005 
Arousal 12.6 6.2 16.8 7.0 -.64 Moderate -4.39 <. 005 
Lubrication 14.5 6.7 18.6 7.5 -.58 Moderate -4.02 <. 005 
Orgasm 10.7 4.9 12.7 5.4 -.39 Small- -2.60 <. 005 
Satisfaction 10.6 4.6 12.8 5.0 -.47 
moderate 
Small- -3.11 <. 005 
Pain 10.1 5.3 13.9 6.2 -.66 
moderate 
Moderate -4.60 <. 005 
Overall score 24.1 9.5 30.5 10.7 -.63 Moderate -4.34 <. 005 
* Sample from Rosen et al., 2000 (40). 
** Effect sizes of 0.20, 0.50, and 0.80 or greater are considered small, moderate and large, respectively 
(Kazis et al., 1989) (41). 
Higher scores reflect better sexual functioning. 
Table 6 displays the correlations between the frequency of fibroid-related 
symptoms and MRI-determined total uterine volume and largest fibroid volume at 
baseline. Urinary frequency/urgency was significantly correlated with total uterine 
volume and largest fibroid volume (r=.37, p=.01 and r=.35, p=.02, respectively), such 
that greater frequency of urinary symptoms is related to larger uterine and fibroid 
volumes. 
Table 6. Correlations between fibroid-related symptoms and MRI-determined total uterine volume and 
largest fibroid volume at baseline (N=46) 
Total uterine volume Largest fibroid volume 
Symptoms r P r P 
Urinary .37 .01* .35 .02* 
Pain -.28 .06 -.28 .06 
Bleeding -.13 .40 -.27 .07 
Bowel -.19 .21 -.28 .06 
Table 7 displays the correlations between SF-36-determined quality of life and 
MRI-determined total uterine volume and largest fibroid volume at baseline. Physical 
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function and general health were significantly correlated with total uterine volume (p= 
.04 in both cases respectively). Bodily pain was significantly correlated with largest 
fibroid volume (p=.02). 
Table 7. Correlations between SF-36-determined quality of life and MRl-determined total uterine volume 
and largest fibroid volume at baseline (N=46) 
Total uterine volume_Largest fibroid volume 
SF-36 scales r P r P 
Physical function .32 .04* .25 .11 
Physical role .08 .63 .11 .48 
Bodily pain .20 .19 .35 .02* 
General health .31 .04* .23 .15 
Vitality .25 .11 .29 .06 
Social function .21 .17 .22 .15 
Emotional role -.07 .66 .06 .71 
Mental health .13 .41 .03 .84 
Table 8 displays the correlations between FSFI-determined sexual function and 
MRJ-determined total uterine volume and largest fibroid volume at baseline. None of the 
FSFI scales - including desire, arousal, lubrication, orgasm, satisfaction, pain or overall 
score - were significantly correlated with either total uterine volume or largest fibroid 
volume. 
Table 8. Correlations between FSFI-determined sexual function and MRl-determined total uterine volume 
and largest fibroid volume at baseline (N=46) 
Total uterine volume_Largest fibroid volume 
FSFI scales r P r P 
Desire .19 .23 .00 1.00 
Arousal .04 .82 .03 .83 
Lubrication -.02 .89 -.12 .91 
Orgasm -.02 .90 -.01 .95 
Satisfaction .03 .87 .02 .88 
Pain .05 .77 .07 .65 
Overall score .04 .81 .02 .89 
In order to investigate whether fibroid location had any effect on fibroid-related 
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symptoms, ANOVAs were performed to test for between-group differences based on 
presence or absence of fibroids in each of two locations. Subserosal and submucosal 
fibroids were chosen because they provided relatively discrete, non-overlapping groups 
(i.e., subserosal fibroids were present in roughly half the women (53%) and absent in 
roughly half the women (47%); the groups with respect to submucosal fibroids were less 
equal in size - 70% (present) and 30% (absent); analysis was not run on intramural 
fibroids because the two groups - those with intramural fibroids present (91%) and those 
with submucosal fibroids absent (9%) - because of insufficient power). No significant 
differences with respect to fibroid-related symptoms were found between patients with 
and patients without subserosal fibroids (Table 9). 
Table 9. Comparison of fibroid-related symptoms in patients with and without subserosal fibroids (SSF) 
using ANOVA 
Presence of SSF (N-23)Absence of SSF (N=20) 
Mean SD Mean SD F P 
Urinary 2.43 1.73 2.25 1.74 .12 .73 
Pain 1.65 1.34 1.75 1.41 .06 .82 
Bleeding .61 1.12 .70 1.30 .06 .81 
Bowel .74 1.10 1.15 1.35 1.21 .28 
No significant differences with respect to fibroid-related symptoms were found between 
patients with and patients without submucosal fibroids (Table 10). 
Table 10. Comparison of fibroid-related symptoms in patients with and without submucosal fibroids (SMF) 
using ANOVA 
Presence of SMF (N=13)Absence of SMF (N=30) 
Mean SD Mean SD F P 
Urinary 2.23 1.64 2.40 1.77 .09 .78 
Pain 1.38 1.26 1.83 1.39 1.00 .32 
Bleeding .85 1.34 .57 1.14 .49 .49 
Bowel .92 1.19 .93 1.26 .00 .98 
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Post-UAE Data 
Thirty-seven patients (71%) completed follow-up questionnaires between one and 
six months post UAE. The questionnaires were identical to the baseline questionnaires. 
The baseline and follow-up groups were not significantly different with respect to age 
(F(1,X)=.85, p=.36), race [X2(l)=0.97, p=.32], education [X2( 1 )= 1.01, p=.32], or 
employment [X2(1)=0.18, p=.67], The baseline and follow-up groups differed with 
respect to marital status [X2( 1)—5.11, p=.02], such that significantly more married or 
cohabiting women participated in the follow-up than did in the baseline survey. 
Seventeen patients (37%) of the baseline sample for which MRI data was 
available (N=46) have completed follow-up MRIs six months post UAE as this thesis 
goes to print. Total uterine and largest fibroid mean volumes at baseline and at six 
months post-UAE are displayed in Table 11, with p values based on t-tests. Mean total 
uterine volume six months post-UAE was 493 cc (range, 100-1304 cc), with a 41% 
volume reduction from baseline. Mean largest fibroid volume six months post-UAE was 
228 cc (range 2-1150 cc), with a 35% volume reduction from baseline. 
Table 11. Means, standard deviations, and paired t-tests for total uterine volume and largest fibroid volume 
at baseline and six months after-UAE 
Baseline (N=46) 6 months post-UAE (N=17) 
Mean SD Mean SD t P 
Total uterine 
volume 
841.69 595.11 492.95 366.27 2.73 .02* 
Largest 
fibroid 
volume 
347.80 352.47 227.54 274.48 2.46 .03* 
In terms of frequency of fibroid-related symptoms post-UAE (Table 12), 49% of 
women reported no urinary frequency/urgency, 54% reported no pain, 70% reported no 
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bleeding difficulties, and 50% reported no bowel problems in the month prior to survey. 
Furthermore, patients reported significantly less urinary frequency/urgency post-UAE 
than at pretreatment (F(l,36=16.59, p<.001), with a 54% decrease in urinary symptoms 
(Table 13). Patients also reported significantly less pain post-UAE than at pretreatment 
(F(l,36)=9.37, p=.003), with a 49% decrease in pain symptoms. 
Table 12. Frequency of fibroid-related symptoms after UAE (N=37) 
Symptoms Not at all 
1/4 of days in 
past month 
1/2 of days in 
past month 
3/4 of days in 
past month 
Everyday in 
past month 
Totals: 1/4 of 
days or more 
N % N % N % N % N % N % 
Urinary 18 48.6 6 16.2 6 16.2 4 10.8 3 8.1 19 51.4 
Pain 20 54.1 8 21.6 4 10.8 1 2.7 4 10.8 17 45.9 
Bleeding 26 70.3 8 21.6 2 5.4 0 0 1 2.7 11 29.7 
Bowel 18 50.0 12 33.3 2 5.6 3 8.3 1 2.8 19 51.4 
Table 13. Univariate analysis of fibroid-related symptoms before and after UAE 
Pre-UAE (N= =52) Post-UAE (N= =37) 
Symptom Mean SD Mean SD F P 
Urinary 2.48 1.65 1.14 1.36 16.59 .000* 
Pain 1.85 1.39 .95 1.33 9.37 .003* 
Bleeding .73 1.25 .43 .83 1.59 .211 
Bowel 1.04 1.19 .81 1.06 .89 .348 
Higher scores reflect worse symptoms (Symptoms scale: 4 = experienced the given symptom every single 
day in the month prior to survey; 3 = experienced the given symptom three-fourths of days in the month 
prior to survey; 2 = experienced the given symptom half the days in the month prior to survey; 1 = 
experienced the given symptom one-fourth of the days in the month prior to survey; 0 = did not 
experienced the given symptom at all in the month prior to survey) 
In terms of quality of life, women reported significantly better physical function 
post-UAE than at pretreatment (F(l,36)=8.11, p=.005), with a 22% improvement in 
physical function (Table 14). Women also reported significantly better quality of life with 
respect to bodily pain post-UAE than at pretreatment (F( 1,36)=10.07, p=.002), with a 
26% improvement in bodily pain. The physical component summary scores of the SF-36 
were also higher post-UAE than at pretreatment (F(l,36)=8.13, p=.006), with a 13% 
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improvement (with higher scores reflecting better quality of life). 
Table 14. Univariate analysis of SF-36-determined quality of life before and after UAE 
Pre-UAE (N=52)Post-UAE (N=37) 
SF-36 scales Mean SD Mean SD F P 
Physical 
function 
77.4 26.0 94.2 28.6 8.11 .005* 
Role 
physical 
66.8 38.2 77.0 31.9 1.76 .188 
Bodily pain 64.2 25.0 80.6 22.6 10.07 .002* 
General 
health 
80.1 14.1 82.3 16.5 .43 .516 
Vitality 49.1 24.6 53.9 23.3 .81 .370 
Social 
function 
76.4 24.1 84.4 19.9 2.68 .106 
Role 
emotional 
78.0 36.6 84.7 32.0 .81 .370 
Mental 
health 
70.9 19.7 74.1 16.2 .60 .440 
Physical 
component 
summary 
score 
47.19 9.34 53.24 9.36 8.13 .006* 
Mental 
component 
summary 
score 
47.94 10.41 48.83 9.20 .16 .70 
Higher scores reflect better quality of life. 
Post UAE, women's reported sexual function was not significantly different than 
at pretreatment in any respect, including desire, arousal, lubrication, orgasm, satisfaction, 
pain, or the overall score. 
Table 15. Univariate analysis of FSFI-determined sexual function before and after 
Pre-UAE (N=52) Post-UAE (N=37) 
FSFI scales Mean SD Mean SD F P 
Desire 5.67 1.87 5.97 2.05 .48 .492 
Arousal 12.51 6.11 10.67 7.61 1.53 .220 
Lubrication 14.44 6.70 11.27 8.95 3.46 .066 
Orgasm 10.45 4.95 8.34 6.29 2.90 .092 
Satisfaction 10.37 4.41 9.10 5.54 1.28 .262 
Pain 9.83 5.19 8.15 6.87 1.63 .205 
Overall 
Score 
23.75 9.38 20.45 12.67 1.81 .182 
Higher scores reflect better sexual function. 
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Changing Trends in Gynecologists’ Opinions of UAE 
Table 16 contains the results of the telephone surveys administered during the two 
time frames. The two survey groups were quite similar. The mean patient ages were 45 
years in the first survey time frame and 44 years in the second. Seventy-five percent of 
respondents to the first survey and 73% of respondents to the second survey had earned at 
least a 4-year college degree (differences not statistically significant, Fisher exact test, 
p>.05). 
According to patients’ perceptions, there was a significant difference in the 
number of gynecologists initially opposed to UAE (pc.05), with fewer gynecologists 
initially opposed to UAE in the second survey in comparison with the first. There was 
also a significant difference in the number of gynecologists who offered UAE as a 
treatment option (pc.05), with more gynecologists offering UAE as a treatment option in 
the second survey in comparison with the first. In addition, as reported by patients, there 
was a significant difference in the number of gynecologists who initiated discussion of 
UAE with their patients in the second survey in comparison with the first. Finally, there 
was no significant difference in the percentage of patients who did not return to 
gynecologists perceived by their patients to be initially opposed to UAE when comparing 
the two surveys. 
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Table 16: Changing trends in patients’ perceptions of gynecologists’ opinions of UAE: telephone survey 
results 
Time Period 
August 1998 to July 2000_July 2000 to April 2002 
Frequency Percent Frequency Percent P 
No. of 
respondents 
21/50 42% 21/39 54% 
Gynecologists 
initially 
opposed to 
UAE 
16/21 76% 7/21 33% <.05 
Gynecologists 
who offered 
UAE as a 
option 
1/21 5% 8/21 38% <.05 
Gynecologists 
who initiated 
discussion of 
UAE 
2/21 10% 9/21 43% <.05 
Patients who 
didn’t return to 
gynecologists 
initially 
opposed to 
UAE 
8/9 89% 5/7 71% Ns 
Ns = not significant 
Participants in the second survey were also queried regarding availability of 
Internet at home and whether they used it to learn about UAE. Seventy-one percent 
(15/21) reported they had Internet access at home, and 62% (13/21) reported that they 
used the Internet to learn about UAE. 
DISCUSSION 
The purpose of this research was to use quantitative MRI data and validated 
instruments to establish baseline radiological, physiological and psychosocial 
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characteristics of premenopausal women with symptomatic uterine fibroids and to follow 
these variables after treatment with UAE. This research represents the largest systematic 
examination of patients undergoing uterine artery embolization for fibroids to date at 
Yale-New Haven Hospital, Department of Diagnostic Radiology, Vascular and 
Interventional Radiology Division. The design of the research has several strengths. First, 
we used MRI to characterize the relationship between uterine and fibroid size and fibroid 
position within the uterus, and fibroid-related symptoms, including quality of life and 
sexual function, which has not been done previously. Second, in terms of quality of life 
and sexual function, we used two empirically validated and reliable questionnaires, the 
SF-36 and the FSFI, to report baseline characteristics of women with symptomatic 
fibroids seeking UAE and compared them to controls to understand these women relative 
to norms. 
Baseline Data 
The first hypothesis of this study was that there is a relationship between baseline 
uterine and fibroid size and fibroid position within the uterus, and baseline fibroid-related 
symptoms - and we sought to define more specifically the nature of this relationship. We 
also hypothesized that women with symptomatic uterine fibroids have worse quality of 
life and sexual function than healthy women controls - and we sought to define more 
specifically the severity of the dysfunction. 
The baseline characteristics of the women participating in our study are similar to 
the results of the largest multi-center prospective UAE study ever to be performed (Pron 
et ai. 555 Canadian women undergoing UAE at eight Ontario university and community 
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hospitals) (42). Our cohort (54% Caucasian, 40% African American, 6% Asian) had an 
average age of 45, similar to the Pron et al cohort (66% Caucasian, 23% black, 11% 
Asian) which had a average age of 43. The only respect in which our cohort was 
considerably different at baseline was with respect to pre-UAE uterine and largest fibroid 
volumes: our cohort had a larger pre-UAE mean total uterine volume (842 cc, versus 704 
cc in the Pron et al cohort) and a larger pre-UAE mean largest fibroid volume (348 cc, 
versus 308 cc in the Pron et al cohort). 
In terms of women’s primary reason for seeking treatment, we found that the most 
common reasons were bleeding (53%), pain (51%), bulk symptoms (31%), urinary 
symptoms (22%), bowel symptoms (4%), and dyspareunia (4%). This information on 
self-reported reasons for seeking treatment is interesting in conjunction with our findings 
about sexual function: while only 4% of our cohort self-reported pain with sexual 
activity, when prompted with multiple-choice questions, the same cohort was found to 
have worse sexual function on every single scale of the FSFI — including pain — than 
healthy controls. A number of possibilities may explain this discrepancy, including: that 
women are not seeking interventional treatment for fibroids because of sexual 
dysfunction; that women do not think of fibroids as a possible cause of their sexual 
dysfunction; that women are not bothered by their sexual dysfunction; or, that women are 
bothered by their sexual dysfunction but are not raising the issue with their physicians. 
Thus, one practical benefit of our study is that it provides evidence in support of 
physicians asking women with fibroids about their sexual health. 
In terms of frequency and percent of symptoms, we found that 81% of women 
reported urinary symptoms at least one-fourth of the days or more in the month prior to 
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the survey. This is similar to the Pron et al UFE trial in which 73% of patients reported 
urinary urgency/frequency at baseline (42). With respect to bleeding, 37% of our cohort 
reported bleeding symptoms at least one fourth of the days or more in the month prior to 
survey. This is also similar to the Pron et al UFE trial, in which 31% of the women 
reported lengthy, i.e., longer than seven days, menstrual periods. 
In terms of quality of life, we found that women seeking UAE for symptomatic 
fibroids reported minimally to moderately worse health-related quality of life with 
respect to physical role, bodily pain, vitality, and social functioning on the SF-36 than the 
general female population. These findings extend the work by Spies et al, who adapted 
the SF-36 for women with uterine fibroids, but found small-to-moderate correlations 
between his fibroid-specific HRQOL measure and the SF-36 when validating his 
instrument (12). Our confirmation utilizing the SF-36, a widely used measure of health 
related quality of life, that women seeking UAE for symptomatic fibroids had worse 
health-related quality of life than healthy women is striking given the prevalence of the 
condition in women of reproductive age. We did, however, find that our cohort of women 
with fibroids had better quality of life with respect to general health than the general 
female population, which may reflect the fact that our cohort with fibroids was largely 
healthy women without other comorbidities. 
In terms of sexual function, we found that women seeking UAE for symptomatic 
fibroids reported worse sexual function in all areas — including desire, arousal, 
lubrication, orgasm, satisfaction and pain — and on the full scale score than healthy 
women controls. This is consistent with a recent population-based cross-sectional study 
by Lippman et al who found that women with fibroids were more likely to report 
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moderate or severe dyspareunia than women without fibroids (43). Spies et al also 
reported that women with fibroids had worse sexual function than normal controls, but 
this conclusion was drawn from answers to a limited number (two) of questions (“During 
the previous three months, how often have your symptoms related to uterine fibroids 
diminished your sexual desire? Caused you to avoid sexual relations?”) (12). Thus, our 
confirmation with the FSF1, an empirically validated 19-item measure of female sexual 
function, that women with symptomatic fibroids have worse sexual function than healthy 
women controls both replicates and extends the work of Spies et al. 
We found that urinary symptoms were related to larger uterine and fibroid size. 
This is particularly relevant given that the present study also found that 81% of women 
reported urinary symptoms at least one fourth of the days or more in the month prior to 
survey. This is an important finding that needs to be followed up with treatment-outcome 
research to examine whether decrease in uterine and fibroid size post-UAE decreases 
urinary as well as other fibroid-related symptoms as well, something our post-UAE data 
only preliminarily begins to investigate. However, in terms of pretreatment data, to our 
knowledge, no published studies exist examining the correlation between baseline uterine 
and fibroid size, and fibroid-related symptoms other than bleeding, including quality of 
life and sexual function. 
In terms of quality of life, we found that three aspects of quality of life - 
including physical function, general health, and bodily pain - were significantly 
correlated with either total uterine volume or largest fibroid volume. The fact that the 
bodily pain scale of the SF-36 was significantly correlated with largest fibroid volume is 
consonant with our finding that pain as a fibroid-related symptoms was significantly 
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correlated with total uterine volume, given that total uterine volume is a function of 
largest fibroid volume plus volume contributed by other fibroids, if present. These 
findings suggest that pain is in some way related to larger volume, potentially because of 
compression from mass effect. The fact that physical function and general health were 
also correlated with total uterine volume implies that beyond individual symptoms, 
fibroids may impact to some degree on overall quality of life depending on the size of the 
uterus. However, the majority of quality of life subscales were not correlated with total 
uterine volume or largest fibroid volume. These results are consistent with Pron et al, 
who asked women to rate the overall impact or interference of fibroids on their daily lives 
on a scale from one (little or minimal interference) to ten (total or complete interference 
with their daily or usual activities), and found that uterine and fibroid size were not 
responsible for high “life impact” scores in some cohorts (42). 
No aspects of sexual function, including pain, were significantly correlated with 
either MRI-determined total uterine volume or largest fibroid volume, despite the fact 
that our cohort of women with fibroids was found to have worse sexual function on every 
FSFI scale than healthy women controls. Lippman et al also reported that total volume of 
fibroids was not related to dyspareunia using different assessment methods (i.e., 
ultrasound-generated volume data and a visual analog scale) (43). Thus, our confirmation 
with MRI and the validated FSFI that pain with respect to sexual function is not 
correlated with volume in women with symptomatic fibroids seeking UAE both 
replicates and extends the work of Lippman et al, who studied a non-care-seeking 
population. This emphasizes that physicians should routinely asking women with fibroids 
about their sexual function, irrespective of uterine or largest fibroid size. More research is 
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needed to better understand what may account for differences in sexual function between 
women with fibroids and women without fibroids (e.g., fibroid neovascularization). 
With respect to fibroid location, our results are consonant with the literature: for 
example, our rate of submucosal fibroids (30%) was similar to that found by Kjerulff et 
al (27% overall) in their pathological analysis of hysterectomy specimens (44). In terms 
of the potential relationship between fibroid location and symptoms, our results do not 
support the contention of some that fibroids located submucosally contribute 
disproportionately to heavy bleeding than fibroids in other locations (7). In contrast, we 
found that the presence of submucosal fibroids did not appear to have a significant effect 
on any fibroid-related symptoms, including bleeding. This is consistent with recent work 
by Wegienka et al who found that nonsubmucosal fibroids were associated with heavy 
bleeding to the same extent as submucosal fibroids (6). Our results also do not support 
the literature that subserosal fibroids contribute disproportionately to pressure and pain. 
In contrast, we found that the presence of subserosal fibroids did not appear to have a 
significant effect on any fibroid-related symptoms, including pain. Although our analysis 
was limited by small sample size, and non-equal groups potentially confounded by the 
presence of fibroids in other locations, our findings suggest that in contrast to 
endometriosis in which the anatomic location of endometriosis does effect pelvic pain 
symptoms (9), the anatomic location of fibroids - specifically those located subserosally 
or submucosally -- does not appear to be related to fibroid-related symptoms. 
Our study of the impact of MRI-determined uterine and fibroid size and fibroid 
position on fibroid-related symptoms, including quality of life and sexual function, adds a 
new dimension to the existing body of literature: although abdominal and transvaginal 
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ultrasound have been used in attempting to characterize the relationship between bleeding 
symptoms and fibroid size and location (6), we are unaware of any published studies that 
utilize MRI to measure the size and location of fibroids while investigating such 
relationships. Dueholm et al found that the mean number of correctly identified myomas 
was significantly higher by magnetic resonance imaging than by transvaginal ultrasound 
(45). 
Post-UAE Data 
The third hypothesis of this research was that uterine and fibroid size would 
significantly decrease after treatment with UAE, and that fibroid-related symptoms would 
improve. However, the small sample size at follow-up post-UAE (37/52=71% for 
questionnaires, 17/46=37% for MRIs) and the possibility of reporting bias among these 
patients limits the reliability of conclusions generated from the data. Results in this arm 
of the research must be considered as preliminary/pilot data only, guiding future research. 
While uterine and largest fibroid volume reductions were 35% and 42% 
respectively three months after UAE in the Pron et al UFE Trial (46) and 34% and 50% 
respectively 4.4 months after UAE in a trial by Spies et al (48), we found a 41% 
reduction in uterine volume and 35% reduction in largest fibroid volume from pre- to 
post-UAE (Figure 2). Thus, despite the limitations of our data, our volume reductions 
were consistent with the literature. 
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In terms of symptom relief, our preliminary data revealed that the most substantial 
improvements were in urinary and pain symptoms, with the frequency of both nearly 
halving from baseline to follow-up: 81% of patients pre-UAE versus 49% of patients 
post-UAE reported urinary frequency/urgency at least one fourth of days per month; 81% 
of patients pre-UAE versus 46% of patients post-UAE reported pain at least one fourth or 
days per month). It would be important for future research to focus on investigating 
whether change in uterine and fibroid volume correlates with changes in fibroid-related 
symptoms. This is of particular interest given findings by de Souza et al that volume 
reduction did not correlate with improvement in fibroid-related symptoms (47), by Pron 
et al that improvements in menorrhagia were unrelated to post-UAE volume reduction 
(46), and by Spies et al that the odds of improved bulk-related symptoms were not 
associated with fibroid-volume change (48). 
Post UAE, we found that quality of life scores improved in all SF-36 scales, with 
a statistically significant improvement in the subscales of physical function and bodily 
pain. Although only preliminary data, significant improvements in these two areas is 

36 
important, given that both were correlated with volume measurements pretreatment (i.e., 
physical function correlated with total uterine volume, p=.04; bodily pain correlated with 
largest fibroid volume, p=.02). This begs the question of whether post-treatment 
improvement in symptoms, including quality of life, correlate with post-treatment 
improvement (i.e., decrease) in uterine and fibroid size, although recent results from de 
Souza et al, Pron et al, and Spies et al detailed above suggest that this may not be the 
case. 
Preliminary results with respect to post-UAE quality of life were consistent with 
the limited literature in this area: Spies et al also found that health-related quality of life 
scores improved at all instances at follow-up post-UAE (48). Our confirmation with the 
SF-36, a widely used measure of health related quality of life, that women reported 
improved health-related quality of life after UAE both replicates and extends the work of 
Spies et al, albeit with a smaller sample size. Our findings in this area are also important 
given mixed reports in the literature about quality of life after hysterectomy, although few 
(six total, two relevant, based on a PubMed search of “hysterectomy” and “SF-36”) 
utilize the SF-36 as we do. While Lambden et al report that women undergoing 
hysterectomy for nononcologic reasons had improved health status and psychological 
well-being as measured by the SF-36 in the initial period after surgery (49), in contrast, 
Byles et al reported that women who had had hysterectomy had significantly poorer 
physical and mental health as measured by the SF-36 quality of life profile than women 
who had not had hysterectomy (50). 
Post UAE, we found no significant change in sexual function in comparison with 
pretreatment. On the one hand, it may be disappointing that there was not an 
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improvement in sexual function given our finding that women with fibroids have 
significantly worse sexual function than normal controls. On the other hand, the results 
are encouraging in light of previous case reports about sexual dysfunction after UAE 
(35). It is also important given recent reports in the literature about sexual dysfunction 
after hysterectomy. Roovers et al reported that the prevalence of one or more bothersome 
sexual problems after vaginal hysterectomy, subtotal abdominal hysterectomy, and total 
abdominal hysterectomy was 43%, 41% and 39%, respectively (51). Additionally, in 
another study comparing total laparoscopic hysterectomy and laparascopically assisted 
vaginal hysterectomy. Long et al found a significant reduction in the frequency of 
orgasms after surgery in both groups (p<.05) (52). These newer studies stand in contrast 
to previous reports by Weber et al, who reported no change in sexual functioning after 
abdominal hysterectomy (53), and by Rhodes et al, who reported that sexual functioning 
improved overall after hysterectomy, with the frequency of sexual activity increasing and 
problems with sexual functioning (e.g., dyspareunia, inorgasmia, low libido) decreasing 
(54). 
Exactly how hysterectomy could cause sexual dysfunction is not clear; both 
abstract and anatomically-based theories have been proposed. First, as Roovers et al 
write, “historically the uterus has been regarded as the regulator and controller of 
important physiological functions, a sexual organ, a source of energy and vitality, and a 
maintainer of youth and attractiveness. Women are concerned that hysterectomy may 
affect their sexual wellbeing or their sexual attractiveness” (51). Second, the pelvic 
autonomic nerve plexus may be damaged during hysterectomy in several ways: during 
division of the cardinal ligaments, the main branches of the nerve plexus that pass under 
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the uterine arteries may be damaged; cervical removal may result in the loss of a large 
part of the nerve plexus; or if a radical hysterectomy is being performed, the major part of 
the vesical innervation may be damaged during blunt dissection of the bladder from the 
uterus and cervix (56, 57). In contrast, UAE avoids the surgical disruption of pelvic nerve 
plexi intimately involved in female sexual response and pleasure. 
Changing trends in gynecologists’ opinion of UAE 
Overtime, we observed that a greater proportion of our UAE patients seemed to 
be referred by gynecologists, rather than self-referred, and therefore the fourth hypothesis 
of our research was that more gynecologists had a favorable opinion of UAE and were 
offering UAE in comparison to two years earlier. Our telephone survey confirmed this 
hypothesis, revealing a trend of increasing acceptance by gynecologists of UAE for 
fibroids, as perceived by their patients. This research extends the literature in this area by 
providing an examination of gynecologists’ changing opinion of UAE over time, albeit 
an indirect one. Since UAE is a relatively new treatment for uterine fibroids, and since 
gynecologists are most often the primary physicians who counsel patients about treatment 
options, their knowledge, attitude and acceptance of UAE as a treatment modality is of 
critical importance. 
Based on patients’ reports of their gynecologists, the following specific trends 
were noted: fewer gynecologists appeared to be initially opposed to UAE in the second 
survey (33%) than in the first (76%); a greater number of gynecologists offered UAE as a 
treatment option in the second survey (38%) than in the first (5%); and a greater number 
of gynecologists initiated discussion of UAE with their patients in the second survey 
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(43%) than in the first (10%). However, despite these significant gains, according to 
patients’ reports, 62% of gynecologists still did not offer UAE as a treatment option for 
fibroids. This is disconcerting, since informed consent dictates discussion of all treatment 
options available. 
Although there appears to be an overall increasing acceptance of UAE by 
gynecologists, there was no significant difference in the percentage of patients who did 
not return to gynecologists perceived by their patients to be initially opposed to UAE 
when comparing the first and second surveys. It may well be that gynecologists who fail 
to discuss UAE or communicate a negative attitude towards the procedure may risk 
losing their patients. 
Seventy-one percent of women in the second survey group had Internet access at 
home, and 62% used the Internet to learn about UAE. Thus, if gynecologists do not 
discuss UAE as a treatment option, it appears that many patients will learn about the 
procedure through the Internet themselves. Physician-conveyed information would 
I 
promote a healthier doctor-patient relationship, as well as counter misinformation 
contained within unregulated Internet sites. 
I 
Limitations 
There are several limitations to our research. First, the study was limited to 
women with fibroids who were symptomatic and seeking interventional treatment. 
Therefore, our results do not necessarily apply to women with fibroids who are 
asymptomatic or symptomatic but seeking non-interventional treatment (i.e., medical 
treatment, myomectomy, hysterectomy). Second, our SF-36 quality of life and FSFI 
: 
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sexual function analyses used historical controls collected by other investigators, and 
therefore were unable to control for potential confounders such as the presence of 
fibroids in women in the control groups. Third, the fact that patients could have had 
other health issues that potentially could have caused pain or urinary symptoms (e.g., 
chronic interstitial cystitis), pressure (e.g., benign ovarian cyst), or bowel symptoms (e.g., 
inflammatory bowel disease), was not controlled for in our analyses. Fourth, we note the 
possibility of reporting bias: some of the patients who underwent UAE left items blank 
on the questionnaire or did not answer the questionnaire at all at follow-up; they might 
have experienced detrimental effects which were not included in analyses. Furthermore, a 
large number of women who completed follow-up questionnaires had not yet reached the 
time, or failed to return, for the six month post-UAE MRI and therefore were also not 
included in analyses. Fifth, our follow-up questionnaire data was accrued between one 
and six months after UAE, instead of at one specific time point. Sixth, we note our small 
sample size. 
In terms of the telephone survey, there were several limitations as well. First, the 
study was limited to women’s perceptions of their gynecologists’ opinion of UAE. 
Therefore, while patients’ perceptions of gynecologists’ opinion of the procedure are 
important in that they may impact whether a patient stays with the same gynecologist, the 
results of this study do not necessarily reflect gynecologists’ actual opinion of the 
procedure. Second, the study was limited to surveying women undergoing UAE at one 
specific practice site, and therefore may reflect locally but not necessarily nationally 
changing trends in gynecologists’ opinion of UAE. 
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CONCLUSIONS 
In summary, in this largely prospective multi-disciplinary study, we examined 
radiological, physiological and psychosocial variables in premenopausal women with 
symptomatic uterine fibroids before and after uterine artery embolization. 
We hypothesized about the relationship between baseline uterine and fibroid size 
and fibroid position, and baseline fibroid-related symptoms. We found that MRI- 
determined uterine and largest fibroid size, but not fibroid position, appear to effect 
urinary symptoms and some aspects of quality of life, but not sexual function. We also 
hypothesized that women with symptomatic uterine fibroids have impaired quality of life 
and sexual function. In addition to urinary, pain, bleeding and bowel symptoms, we 
found that women with symptomatic fibroids had worse quality of life and sexual 
function than healthy controls. Based on these findings, it is recommended that health 
care providers treating women with uterine fibroids specifically ask about quality of life 
and sexual function, because women may be unaware of their impaired function or may 
not raise the issue themselves. 
Post-UAE, we hypothesized that there would be a decrease in uterine and fibroid 
size, and an improvement in fibroid-related symptoms. We found that uterine and fibroid 
volume decreased significantly, and that their were significant improvements in urinary 
and pain symptoms, as well as some aspects of quality of life. Future research tracking 
fibroid-related symptoms, including quality of life and sexual function should be 
performed in a consistent manner before and after a variety of treatment modalities, in 
order to establish evidence-based treatment guidelines. 
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In view of our telephone survey results that more gynecologists had a favorable 
opinion of UAE and were offering UAE currently in comparison to two years previously, 
it is recommended that Interventional Radiologists treating women with UAE continue to 
work actively to create a positive relationship with gynecologists, involving the referring 
MD before, during and after the UAE procedure, in order to enhance the acceptance of 
this safe, effective procedure. 
In conclusion, our research illustrates that women with symptomatic leiomyomata 
seeking UAE are burdened with troublesome fibroid-related symptoms and impaired 
quality of life and sexual function. UAE, increasingly accepted by gynecologists, reduces 
uterine and fibroid volume and provides improvement in fibroid-related symptoms, 
including some aspects of quality of life, without worsening sexual function. Continued 
multidisciplinary research such as this involving radiologists, gynecologists and 
psychologists has the potential to greatly assist physicians and patients alike to make 
more informed decisions about the treatment of this highly prevalent women’s health 
condition. 
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Changing Trends in Gynecologists' Opinions of 
Uterine Artery Embolization for Fibroids: The 
Patient's Perspective 
Elizabeth Kagan Arleo, BA, Jeffrey Poliak, MD, and Michael G. Tal, MD 
This study's purpose was to survey patients' perceptions of gynecologists' opinions of uterine artery embolization 
(UAE) for fibroids. Twenty-one women who underwent UAE between July 2000 and April 2002 and 21 women who 
underwent UAE between September 1998 and July 2000 completed questionnaires. Each woman was asked what her 
gynecologist's initial opinion was toward UAE, what treatment options were offered, who initiated discussion of UAE, 
and whether she returned to the same gynecologist after UAE. As of 2002, more gynecologists had a favorable opinion 
of UAE and were offering UAE versus in the year 2000. The majority of patients whose gynecologists initially opposed 
UAE did not return to the same gynecologists, reflecting a similar trend noted 2 years earlier. 
J Vase Interv Radiol 2003; 14:1559-1561 
Abbreviation: UAE = uterine artery embolization 
GIVEN that gynecologists have tradi¬ 
tionally been the providers of treat¬ 
ment for uterine fibroids, the purpose 
of this article is to investigate gyne¬ 
cologists' opinion of uterine artery em¬ 
bolization (UAE), a relatively new 
treatment option provided by inter¬ 
ventional radiologists. Uterine fi¬ 
broids, also known as leiomyomata, 
affect 30%-40% of women of repro¬ 
ductive age in the United States (1). 
Fibroids are symptomatic in 35%-50% 
of women who have them, causing 
menorrhagia, pressure-related symp¬ 
toms (bloating, urinary frequency or 
retention, constipation), pain (dys¬ 
menorrhea, dyspareunia), and repro¬ 
ductive difficulties (infertility, miscar¬ 
riage). Medical treatment options for 
symptomatic fibroids include gonado- 
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tropin-releasing hormone analogues 
(2) and, more recently, danazol and 
gestrinone (3), whereas surgical treat¬ 
ment options include hysterectomy 
and myomectomy. More recently, 
UAE, a minimally invasive alternative 
therapy performed by interventional 
radiologists, has been used as a pri¬ 
mary treatment for symptomatic uter¬ 
ine fibroids. Hysterectomy is currently 
the most common surgical treatment 
for women with uterine fibroids, and 
fibroids are the number-one indication 
for performing hysterectomy: 40% of 
the estimated 600,000 hysterectomies 
performed annually in the United 
States are performed for fibroids (4). 
UAE for fibroids, first described by 
Ravina et al in 1995 (5), has been gain¬ 
ing popularity for several reasons: the 
procedure is minimally invasive with 
little blood loss, is associated with less 
morbidity, requires shorter hospital¬ 
ization during recovery, and allows 
for preservation of the uterus (6-13). 
However, the American College of 
Obstetricians and Gynecologists Prac¬ 
tice Bulletin, which provides clinical 
management guidelines for obstetri¬ 
cians and gynecologists, states that 
"uterine artery embolization is re¬ 
garded as investigational" (14). How¬ 
ever, anecdotal evidence suggests that 
gynecologists' opinions may be chang¬ 
ing over time as more women seek 
uterine-preserving treatments for 
symptomatic fibroids. 
Given the prevalence of fibroids, 
the increasing role of UAE in treating 
them, and the lack of data examining 
gynecologists' opinion of the proce¬ 
dure, the aims of the present study 
were to survey patients' perceptions of 
their gynecologists' expressed opin¬ 
ions of UAE and to compare these re¬ 
sults to those of the same survey con¬ 
ducted 2 years earlier. 
MATERIALS AND METHODS 
In August 1998, a telephone study 
was initiated to assess patients' per¬ 
spective of their gynecologists' opin¬ 
ion of UAE and to examine changing 
trends, if any. The surveys were ad¬ 
ministered during two time frames: 
from August 1998 to July 2000 and 
from July 2000 to April 2002. Twenty- 
one patients completed the survey 
during each time frame. 
For entry into the study, patients 
were required to have undergone 
UAE for symptomatic uterine fibroids 
at the practice site and be participating 
in another survey regarding UAE con¬ 
ducted by the same principal investi- 
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Telephone Survey Results 
Time Period 
August 1998 to July 2000 to 
July 2000 April 2002 P Value 
No. of respondents 21/50 (42) 21/39 (54) 
Gynecologists initially 
opposed or strongly 
opposed to UAE 
16/21 (76) 7/21 (33) <.05 
Gynecologists who offered 
UAE as a treatment option 
1/21 (5) 8/21 (38) <.05 
Gynecologists who initiated 
discussion of UAE with 
their patients 
2/21 (10) 9/21 (43) <.05 
Patients who did not return to 
gynecologists who were 
initially opposed to UAE 
8/9(89) 5/7(71) NS 
Note.—Values in parentheses are percentages. 
gators. Patients were self-referred or 
referred by gynecologists for treat¬ 
ment. Exclusion criteria were malig¬ 
nancy and postmenopausal status. 
Each participant was asked to rate 
her gynecologist's initial opinion of 
UAE before the procedure on a scale 
from 1 (strongly opposed) to 6 (very 
favorable) or 7 (unaware of the proce¬ 
dure); whether the gynecologist of¬ 
fered UAE as a treatment option; 
whether she or the gynecologist initi¬ 
ated discussion of UAE; and whether 
she continued to see the same gynecol¬ 
ogist after the procedure. In the sec¬ 
ond survey, each participant was also 
asked whether she had Internet access 
at home and whether she used the 
Internet to learn about UAE. 
Data were analyzed with use of 
Statcalc 1.1 (StatCalc Software, Etext. 
net publisher, Venice, CA). Frequency 
and percentiles were calculated for 
categoric variables. All reported P val¬ 
ues were based on Fisher exact tests. 
The study was reviewed and ap¬ 
proved by the hospital's human inves¬ 
tigation committee. 
RESULTS 
The two survey groups were quite 
similar. The mean patient ages were 
45.4 years in the first survey and 44.2 
years in the second. Seventy-five per¬ 
cent of respondents to the first survey 
and 73% of respondents to the second 
survey had earned at least a 4-year 
college degree (differences not statisti¬ 
cally significant, Fisher exact test, P > 
.05). 
The Table contains the results of 
the telephone surveys during both 
time frames. There was a significant 
difference in the number of gynecolo¬ 
gists initially opposed to UAE (P < 
.05), with fewer gynecologists initially 
opposed to UAE in the second survey 
in comparison with the first. There 
was also a significant difference in the 
number of gynecologists who offered 
UAE as a treatment option (P < .05), 
with more gynecologists offering UAE 
as a treatment option in the second 
survey in comparison with the first. In 
addition, there was a significant differ¬ 
ence in the number of gynecologists 
who initiated discussion of UAE with 
their patients (P < .05), with more gy¬ 
necologists initiating discussion of 
UAE with their patients in the second 
survey in comparison with the first. 
Finally, there was no significant differ¬ 
ence in the percentage of patients who 
did not return to gynecologists who 
were initially opposed to UAE when 
comparing the two surveys. 
Participants in the second survey 
were also queried regarding whether 
they had the Internet at home and 
whether they used the Internet to 
learn about UAE. Seventy-one percent 
(15 of 21) reported they had Internet 
access at home, and 62% (13 of 21) 
reported that they used the Internet to 
learn about UAE. 
DISCUSSION 
This study revealed a trend of in¬ 
creasing acceptance by gynecologists 
of UAE for treatment of symptomatic 
uterine fibroids. This research extends 
the literature in this area by providing 
an examination of gynecologists' 
changing opinions of UAE over time. 
Because UAE is a relatively new treat¬ 
ment for uterine fibroids, and because 
gynecologists are most often the pri¬ 
mary physicians who counsel patients 
about treatment options, their knowl¬ 
edge, attitude, and acceptance of UAE 
as a treatment modality is of critical 
importance. 
With regard to specific trends, it 
was found that fewer gynecologists 
were initially opposed to UAE in the 
second survey (33%) than in the first 
(76%). In addition, there was a greater 
number of gynecologists offering UAE 
as a treatment option in the second 
survey (38%) than in the first (5%), and 
a greater number of gynecologists ini¬ 
tiated discussion of UAE with their 
patients in the second survey time 
frame (43%) than in the first (10%). 
Despite these significant gains, 62% of 
gynecologists still do not offer UAE as 
a treatment option for fibroids. This is 
disconcerting because informed con¬ 
sent dictates discussion of all treat¬ 
ment options. 
Although there appears to be an 
overall increasing acceptance of UAE 
by gynecologists, there was no signif¬ 
icant difference in the percentage of 
patients who did not return to gyne¬ 
cologists initially opposed to UAE 
when comparing the first (50%) and 
second (71%) surveys. It may well be 
that gynecologists who fail to discuss 
UAE or communicate a negative atti¬ 
tude toward the procedure may risk 
losing their patients. 
Seventy-one percent of participants 
had Internet access at home, and 62% 
of participants used the Internet to learn 
about UAE. Therefore, if gynecologists 
do not discuss UAE as a treatment op¬ 
tion, it appears that many patients will 
learn about the procedure through the 
Internet anyway. Up-front physician- 
conveyed information would promote a 
healthier doctor-patient relationship as 
well as counter misinformation some¬ 
times present on unregulated Internet 
sites. 
There are several limitations to this 
study. First, the study was limited to 
women's perceptions of their gynecol¬ 
ogists' opinions of UAE. Therefore, al¬ 
though patients' perceptions of gyne¬ 
cologists' opinions of the procedure 
are important in that they may impact 
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whether patients stay with the same 
gynecologists, the results of this study 
do not necessarily reflect gynecolo¬ 
gists' actual opinions of the procedure. 
Second, because the study was limited 
to women with fibroids that were 
symptomatic to the extent that inter¬ 
ventional treatment was sought, the 
results of this study do not necessarily 
apply to the gynecologists of women 
with fibroids that were asymptomatic 
or symptomatic but did not prompt 
operative treatment. The treatment op¬ 
tions and opinions offered by these 
gynecologists may have been differ¬ 
ent. Third, the study was limited to 
surveys of women undergoing UAE at 
one specific practice site and therefore 
may reflect locally but not necessarily 
nationally changing trends in gynecol¬ 
ogists' opinions of UAE. 
In conclusion, a trend of increasing 
acceptance by gynecologists of UAE 
for treatment of symptomatic uterine 
fibroids was found. It is recommended 
that interventional radiologists treat¬ 
ing women with UAE work actively to 
create positive relationships with gy¬ 
necologists and make an effort to get 
them involved before, during, and af¬ 
ter the UAE procedure. In this way, 
the trend of greater acceptance of this 
safe, effective procedure for the treat¬ 
ment of this highly prevalent women's 
health condition will be enhanced. 
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Relationship between Fibroid Location arid Volume, and Fibroid-Related 
Symptoms: Oo Position or Size Matter? 
@ 
E.K. Artec, MD, New Haven, CT • R.M. Masheb, PhD * J.S. Poliak, MD • S.M. 
McCarthy, MD, PhD • M.G. Tal, MD (Michael.tal@yale.edu) 
PURPOSE: To determine the relationship between MRI-determined fibroid 
location, largest fibroid volume (LFV) and total uterine volume (TUV), and 
fibroid-related symptoms in premenopausal women with symptomatic 
uterine fibroids. 
METHOD AND MATERIALS: Eighty premenopausal women undergoing 
uterine fibroid embolization (UFE) received a pre-procedural pelvic MR1 
and self-report questionnaire investigating the frequency of fibroid-related 
symptoms, including pain, urinary, bowel, and bleeding symptoms. From 
MRIs, the presence of submucosal fibroids (SMF), intramural fibroids with 
a submucosal component (TMFSC), intramural fibroids (IMF), Subserosal 
fibroids with an intramural component (SSFIC), and subserosal fibroids 
(SSF) were noted, and LFV and TUV were calculated. The frequencies of 
fibroids in the different locations defined above and the frequencies of 
fibroid-related symptoms in the month prior to UFE were calculated. 
Statistical analyses were then performed to determine whether there were 
relationships between fibroid location, LFV and TUV, and fibroid-related 
symptoms. 
RESULTS: Ninety-two percent of patients had IMF, 56% had SSF, 26% had 
IMFSC, 26% had SMF, and 5% had SSFIC. Pain was associated with the 
presence of IMFSC (p=.013). Pain, urinary, bowel, and bleeding symptoms 
were not significantly associated with the presence of fihroids in any other 
locations. LFV and TUV were significantly correlated with urinary symp¬ 
toms (p = .017 and p= .007, respectively). There was no correlation between 
LFV or TUV and pain, bowel, and bleeding symptoms. 
CONCLUSIONS: In premenopausal women with symptomatic uterine 
fibroids, there was a significant relationship between fibroids located 
intramurally with a submucosal component and pain symptoms, as well as 
between fibroid and uterine volume, and urinary symptoms. No other 
significant relationships were found. 
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092. Relationship between Uterine and Fibroid Volume and Fibroid- 
Related Symptoms and Sexual Functioning in Premenopausal 
Women with Leiomyomata 
Arleo E.K_1Masheb R.2; Tal M.G.1 1. Department of Radiology, Yale University, 
New Haven, CT; 2. Department of Psychiatry, Yale University, New Haven, CT 
Objectives: To determine the relationship between uterine and fibroid volume, and 
fibroid-related symptoms and sexual functioning in premenopausal women with 
leiomyomata. 
Methods: Women undergoing UFE for leiomyomata received a pre-operative MRI 
and self-report questionnaires. Total uterine volume (TUV) and largest fibroid vol¬ 
ume were obtained from pre-operative MRIs. Participants completed a question¬ 
naire of fibroid-related symptoms including pelvic pain, urinary and bowel 
symptoms, and bleeding. In addition, participants completed the Female Sexual 
Functioning Index (FSFI), an empirically validated measure including subscales 
for sexual desire, arousal, lubrication, otgasm, satisfaction, and dyspareurua. The 
frequencies of fibroid-related symptoms in the month prior to UFE, and mean 
scores for each subscale of the FSFI, were calculated. Relationships between the 
two volumes, and the fibroid-related symptoms and FSFI subscales were examined 
using Pearson correlation coefficients. 
Results: Thirty women with confirmed leiomyomata received pre-operative MRIs 
and completed the questionnaires. TIUV was moderately correlated with urinary 
symptoms (r=.40) and several aspects of sexual functioning, including sexual de¬ 
sire, orgasm and dyspareurua (r=.47, .48 and .50, respectively) at least at the .05 
level. However, the volume of the largest fibroid did not correlate significantly 
with either fibroid-related symptoms or sexual functioning. 
Conclusions: TUV, but not fibroid volume, was related to urinary symptoms and 
aspects of sexual functioning in premenopausal women with leiomyomata. 
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Quality of Life and Sexual 
Functioning in Premenopausal 
Women With Leiomyomata 
Elizabeth Kagan Arleo 
Yale University School of Medicine, New Haven, CT 
Robin M. Masheb, PhD, and Michael Tal, md 
OBJECTIVE: To characterize quality of life and sexual func¬ 
tioning in premenopausal women with leiomyomata. 
METHODS: Women undergoing uterine fibroid embolization 
(UFE) for leiomyomata received a preoperative MRI and 
health-related quality of life and sexual functioning question¬ 
naire. The questionnaire contained empirically validated mea¬ 
sures, including the Short Form 36 (SF-36) and the Female 
Sexual Functioning Index (FSFT). Mean scores for each sub¬ 
scale of the SF-36 and FSFI were calculated and effect sizes were 
computed, using norms for healthy and patient populations. In 
addition, correlations with total intrauterine volume (TIUV), 
obtained from preoperative MRIs, and subscales from the FSFI 
were computed. 
RESULTS: Forty women with confirmed leiomyomata com¬ 
pleted the quesdonnaire. Differences in quality of life scores 
between women with leiomyomata and the US female popula¬ 
tion were small. However, differences in sexual functioning 
scores between women with leiomyomata and healthy women 
were significant on all subscales, at least at the .05 level, with 
effect sizes ranging from medium to large ( — 0.42 to —1.16). 
Furthermore, women with leiomyomata did not significantly 
differ from women with female sexual arousal disorder with 
respect to dyspareunia. Among women with leiomyomata, 
several aspects of sexual functioning were significantly related 
toTTUV, including desire, orgasm, and dyspareunia {P= .026, 
.021, and .019, respectively). 
CONCLUSIONS: Participants with leiomyomata had health- 
related quality of life comparable to that of the general popula¬ 
tion. However, their sexual functioning was below that of 
healthy women, especially with regard to dyspareunia. 
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Reiationship between Uterine and Fibroid Volume, and 
Fibroid-Related Symptoms and Sexual Functioning in 
PreMenopausal Women with Leiomyomata. 
E.K. Arleo, Yale University, New Haven, CT, USA • R. 
Masheb • J. Poliak • M. G. Tal 
PURPOSE: To determine the relationship between uterine 
and fibroid volume, and fibroid-related symptoms and sexual 
functioning in premenopausal women with leiomyomata. 
MATERIALS AND METHODS: Women undergoing UFE for 
leiomyomata received a pre-operative MRI and self-report 
questionnaires. Total uterine volume (TUV) and largest fibroid 
volume were obtained from pre-operative MRIs. Participants 
completed a questionnaire of fibroid-related symptoms 
including pelvic pain, urinary and bowel symptoms, non- 
menstrual bleeding and hot flashes. In addition, participants 
completed the Female Sexual Functioning Index (FSFI) 
empirically validated measure including subscales forsexmi 
desire, arousal, lubrication, orgasm, satisfaction, and 
dyspareunia. The frequencies of fibroid-related symptoms m 
the month prior to UFE, and mean scores for each subscale of 
the FSFI, were calculated. Correlations between the two 
volumes, and the fibroid-related symptoms and FSFI subscab 
were then computed. 
RESULTS: Thirty women with confirmed leiomyomata 
received pre-operative MRIs and completed the 
questionnaires. TUV was significantly correlated with unnan 
symptoms (p=.038) and several aspects of sexual functioning, 
including sexual desire, orgasm and dyspareunia (p=.026, .021 
and .019, respectively). However, the volume of the largesi 
fibroid was not significantly correlated with either fibroid- 
related symptoms or sexual functioning. 
CONCLUSION: TUV, but not fibroid volume, was related to 
urinary symptoms and aspects of sexual functioning in 
premenopausal women with leiomyomata. 
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Changing Trends in Gynecologists Opinion of Uterine 
Fibroid Embolization (UFE). 
E.K. Arleo, Yale University, New Haven, CT, USA •M.G. 
9 Tal 
fi PURPOSE: To evaluate the current opinion of gynecologists 
|| towards UFE, as perceived by patients, and compare it to the 
opinion of gynecologists towards UFE two years ago. 
i |- MATERIALS AND METHODS: Twenty-one women that 
I underwent UFE between 7/00 to 4/02, completed a telephone 
i survey thus far. They were asked what their gynecologists 
l; opinions were towards UFE, both before and after the 
% procedure. In addition, they were asked if they see the same 
|| gynecologists that they saw before the procedure, what 
% treatment options were offered to them and whether they or 
if their gynecologist initiated discussion of UFE. These data 
I were then compared to data obtained previously from 21 
1. women that underwent UFE between 8/98 to 7/00. 
RESULTS: Thirty-three percent (7/21) of gynecologists 
initially opposed or strongly opposed UFE, in contrast to 
76% (16/21) of gynecologists from two years ago, this 
difference is statistically significant (p<0.05). Seventy-one 
percent (5/7) of the patients did not return to the gynecologists 
that were initially opposed to the procedure and are now 
seeing other gynecologists. This is similar to data from two 
years ago, where 89% (8/9) of the patients did not return to 
the gynecologists that remained opposed to the procedure. 
While all gynecologists offered hysterectomy, just as they did 
two years ago, 38% (8/21) also offered UFE, in contrast to 
only 5% (1/21) of gynecologists two years ago, the difference 
is statistically significant (p<0.05). Forty-three percent (9/ 
21) of physicians initiated the discussion of UFE with their 
patients, a statistically significant increase from two years 
ago, when only 10% (2/21) of the physicians initiated 
discussion with their patients (p<0.05). 
CONCLUSION: More gynecologists are offering UFE as a 
treatment option for uterine fibroids and more have a favorable 
opinion towards UFE than two years ago. The majority of 
patients who underwent UFE whose gynecologist opposed 
the procedure did not continue seeing the same gynecologist, 
reflecting a similar trend as two years ago. 
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By Diana Barnes Brown for Fibroidsl 
A recent study conducted by Dr. Michael Tal and Elizabeth Kaaan Arleo of the 
Yale University School of Medicine’s Department of Diagnostic Radiology 
presented some positive findings about the efficacy and rates of doctor approval 
of uterine fibroid embolization (UFE) for uterine fibroids. 
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UFE is a minimally invasive procedure that can usually be performed on an 
outpatient basis. The procedure involves the use of a catheter that is fed through 
the femoral artery to the uterine artery and then used to administer a solution 
that blocks blood flow to the fibroid. Because fibroids require a relatively large 
quantity of blood to grow and survive in the uterus, blockage of blood flow to 
fibroids results in their shrinkage and the disappearance of symptoms for most 
patients, without requiring further treatment or the use of more invasive methods, 
such as hysterectomy. 
The study, published in the December, 2003 issue of the Journal of Vascular and 
Interventional Radiology, showed that from 2000 to 2002, patients’ perspectives 
about their gynecologists’ opinions of UFE for fibroid tumors changed markedly. 
In a 2000 survey of 21 women, three quarters of those surveyed answered that 
they thought their gynecologists were opposed to UFE, while in a similar survey 
conducted in 2002, only a third of respondents answered that they thought their 
gynecologists were opposed to the use of UFE. 
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According to Dr. Tal. the jump in the treatment’s popularity can be attributed to 
rising doctor and patient awareness, and also to innovations in embolization 
techniques and technologies, such as increased research and development of 
embolic agents, the solutions made up of tiny plastic particles that flow to 
targeted areas, blocking blood supply and thus shrinking fibroids. For this 
reason, he believes that doctors should discuss UFE with all patients who suffer 
from symptomatic uterine fibroids. 
But, adds Ms. Arleo, over half of doctors are still reluctant to recommend UFE as 
a treatment option, a trend which she comments, is "disconcerting, especially 
since informed consent dictates discussion of all treatment options available." 
The pair expressed hope that physicians will increasingly regard UFE as a viable 
and advantageous treatment option for patients. 
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Highlights from December 's Journal of Vascular and 
Interventional Radiology 
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Contact Information 
Available for logged-in reporters only 
Description 
1) Superselective microcoil embolization for the treatment of lower gastrointestinal hemorrhage is a safe and 
effective treatment - study results show a far lower complication rate than surgery. 2) Changing trends in 
gynecologists opinions of UAE. 
Newswise — Acute lower gastrointestinal hemorrhage (LGI) is a potentially life threatening condition. Most cases 
can be managed medically, but 10 - 15 percent require intervention to control the bleeding. The treatment of LGI 
hemorrhage has traditionally been surgical and the high morbidity and mortality from bowel resection is well- 
documented - as high as 15-30 percent in emergent operations. These patients are usually an older population 
at higher surgical risk. Other treatment options also have limitations. Vasopressin infusion, a drug that constricts 
the blood vessels, is associated with high rates of rebleeding and multiple side effects. In massive hemorrhage, 
endoscopy is limited because the presence of blood and stool may prevent visualization of the source of bleeding. 
However, embolization offers a highly effective and minimally invasive treatment to control the hemorrhage. 
Because interventional radiologists utilize X-ray imaging to guide the catheter inside the body to the site of 
bleeding, visualization in massive bleeding is not an issue. 
Superselective embolization involves mechanically blocking the blood flow to the hemorrhage area through the 
deployment of tiny coils delivered via a catheter. Interventional radiologists use embolization in many areas of the 
body to block blood flow to tumors or to treat traumatic or postpartum hemorrhage. The adjacent blood supply 
from non-target vessels continues to provide sufficient blood flow to the affected organ. However, the weaker 
blood supply of the LGI tract may predispose the colon to an increased risk of ischemia. 
Advances in microcatheter technology such as microcatheters and finer guidewires, coupled with advances in 
digital flouroscopic imaging, have resulted in vast improvements in this technique, allowing for superselective -- 
more precise -catheterization while preserving the adjacent blood flow to the bowel. 
The study reports the authors’ experience with superselective embolization and a review of the literature. A 
combined meta-analysis of 144 superselective microcoil embolizations showed a minimal risk of significant 
ischemic complication when a modern transcatheter technique is used. The post-embolic infarction rate was 
estimated as zero percent. In light of these results, and until further studies demonstrate a superior alternative 
treatment, massive LGI hemorrhage should be treated with attempted superselective microcoil embolization to 
control bleeding. 
Changing Trends in Gynecologists Opinions of Uterine Artery Embolization for Fibroids: The Patients Perspective 
Interventional radiologists at the Yale University School of Medicine surveyed their uterine artery embolization 
patients’ to determine their gynecologist’s opinion of uterine artery embolization (UAE), a relatively new treatment 
option for uterine fibroids. Traditionally gynecologists have been the providers of treatment for uterine fibroids, 
however interventional radiologists perform uterine artery embolization, a minimally invasive procedure that blocks 
the blood flow to the fibroid, causing it to shrink. Twenty-one women who underwent UAE between September 
1998 and July 2000 and 21 between July 2000 and April 2002 completed questionnaires. Each woman was asked 
what her gynecologist’s initial opinion was toward UAE, what treatment options were offered, who initiated the 
Keywords 
MEDICAL ADVANCE FOR LOWER Gl 
HEMORRHAGE UTERINE FIBROIDS 
GYNECOLOGISTS 
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discussion of UAE, and whether she continued to use the same gynecologist after UAE. 
As of 2002, more gynecologists had a favorable opinion of UAE and were offering it versus in the first survey time 
period. In the second survey period, 38 percent were offering UAE as a treatment option, compared with 5 
percent in the first survey. Despite this progress, 62 percent of gynecologists still did not offer UAE as a treatment 
option for fibroids. This is disconcerting because informed consent dictates discussion of all treatment options. 
The majority of patients whose gynecologists initially opposed UAE did not continue to use that gynecologist, 
reflecting a similar trend noted two years earlier. 
See http://jvir.org for abstracts. 
© 2004 Newswise All Rights Reserved. 
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BioSphere Medical, Inc. (ticker: BSMD, exchange: NASDAQ) News 
Release - 8-Dec-2003 
BioSphere Medical Reports Study Published in Journal of Vascular and 
Interventional Radiology 
ROCKLAND, Mass.-(BUSINESS WIRE)~Dec. 8, 2003- 
Study Indicates Increasing Acceptance by Gynecologists of UFE 
as Treatment for Symptomatic Uterine Fibroids 
BIOSPHERE MEDICAL, (NASDAQ:BSMD), Approximately 20-40 
percent of women 35 years and older experience uterine fibroids 
and approximately 50% of African-American women have fibroids. 
All too frequently, a woman with symptomatic fibroids faces a 
hysterectomy or myomectomy to relieve her symptoms caused by 
the fibroids. More recently, a minimally invasive procedure called 
uterine fibroid embolization (UFE) has become widely available. 
UFE, which is performed by an Interventional Radiologist, is a 
uterus-saving procedure using a catheter and an embolic agent, 
such as BioSphere Medical's Embosphere(R) Microspheres, to cut 
off the blood supply to the fibroid tumors. Symptoms, such as 
excessive bleeding and pelvic pain, are relieved as the fibroids 
shrink. 
Some of the initial challenges to the growth of UFE procedures 
have been due to a lack of physician and patient awareness. 
However, a recent article published in the December 2003 issue of 
the Journal of Vascular and Interventional Radiology reveals a 
more positive trend for gynecologists to offer UFE as a first line 
therapy for fibroid patients, which is expected to help fuel market 
growth of this procedure. 
Dr, Michaei Tal and Elizabeth Kagan Arleo from the Department of 
Diagnostic Radiology, section of Interventional Radiology at Yale 
University School of Medicine performed a baseline patient survey 
in July 2000 and repeated the survey in April 2002 to investigate if 
women believed that their gynecologist were discussing and 
offering UFE as a treatment option. Both surveys analyzed the 
results of 21 patients, for a total of 42 patients. The survey asked 
questions related to their gynecologist's initial opinion of UFE, 
which treatment options were offered, who initiated the discussion 
of UFE, and whether the patient returned to the same gynecologist 
after her UFE. The initial survey in 2000 showed that 76% of their 
patient's believed that their gynecologists were opposed or 
strongly opposed to UFE as an option. The updated survey in 
2002 suggests that only 33% of patients believed that their 
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=BSMD&script=410&layout=-6&item_i... 2/7/04 
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gynecologists were opposed or strongly opposed to UFE. In 2000, 
the patients in the survey indicated that approximately 5% of 
gynecologists offered UFE as a treatment option whereas in April 
2002, this number increases to 38%. 
"UFE is clearly a benefit to women who are suffering the 
debilitating effects of fibroids, but are hesitant to having major 
surgery," indicates Dr. Tal. "The process of performing UFE has 
improved tremendously since 1998; thus, gynecologists should be 
including UFE in treatment discussions with all fibroid patients. 
Interventional radiologists have drastically improved patient care, 
pain management, and patient selection over the course of almost 
a decade." 
Elizabeth Kagan Arleo, fourth year medical student at Yale. 
comments, "The fact that 62% of gynecologists still do not offer 
UFE as a treatment option is disconcerting, especially since 
informed consent dictates discussion of all treatment options 
available." 
Dr. Tal concludes, "Uterine fibroid embolization is a less invasive 
and safer treatment option in women with symptomatic fibroids 
than surgery. The trend toward gynecologist acceptance of this 
safe procedure should only enhance the patient’s overall quality of 
ii 
For more information on uterine fibroid embolization, go to 
www.ask4ufe.com or call toll free. 1-877-ASK-4UFE. 
About BioSphere Medical, Inc. 
BioSphere Medical, Inc., based in Rockland, Massachusetts, is a 
medical device company focused on applying our proprietary 
microsphere technology to medical applications using 
embolotherapy techniques. Our core technologies, patented bio- 
engineered polymers and manufacturing methods, are used to 
produce miniature spherical beads with uniquely beneficial 
properties for a variety of medical applications. Our principal focus 
is the treatment of symptomatic uterine fibroids using a procedure 
called uterine fibroid embolization, or UFE. Our products are 
already beginning to gain acceptance in this rapidly emerging 
procedure as well as in a number of other new and established 
medical treatments. Our strategy is two fold. First, we are seeking 
to grow the embolotherapy business worldwide, specifically the 
UFE procedure, by increasing awareness of availability of this 
procedure. Second, we are seeking to maintain our current 
technology leadership by the continuous introduction of new 
products and product improvements, both through internally 
developed and externally acquired technologies, that improve and 
broaden the use of embolotherapy techniques. 
We have received clearance in a number of countries, including 
the United States, Canada, Australia and the European 
Community, which allow us to sell our products for use in general 
embolization procedures, including uterine fibroid embolization. 
Cautionary Statement Regarding Forward-Looking Statements - 
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Interventional rads pot faith in UFE 
marketing, research despite skepticism of 
ob/gyns 
6/13/03 
By: Trade L. Thompson 
It was less than a decade ago that interventional radiologists reported 
their first experience with a new procedure for treating noncancerous 
but symptomatic uterine fibroids, or leiomyomas. 
French practitioners had been routinely embolizing the uterine arteries 
of patients scheduled for myomectomy - seeking to reduce 
hemorrhage during the subsequent surgery -- when they noticed that 
embolization itself tended to shrink the problematic fibroids. Surgeries 
were canceled and a less-invasive treatment was born. 
Worldwide as many as 35,000 uterine fibroid embolizations (UFE), 
also known as uterine artery embolizations (UAE), have been 
performed since then, and the pace quickens every year. Yet UFE 
procedures are still dwarfed by long-standing surgical approaches in 
the U.S., where every year some 200,000 women undergo 
myomectomy or hysterectomy for fibroids. 
sponsor 
sponsor 
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A basic diagram of a UFE procedure. A nick is made in the skin and 
a catheter is inserted into the femoral artery. The catheter, which is 
guided through the artery with real-time imaging, releases tris-acryl 
gelatin microspheres into the blood vessel feeding the fibroid. Image 
courtesy of SIR. 
Interventional radiologists believe many of these patients would be 
good candidates for UFE, but the situation is dd)d vu all over again for 
radiology. That is, the physicians who "control" most of these patients 
generally don’t refer them out. 
The American College of Obstetricians and Gynecologists describes 
UFE as investigational in its most recent practice bulletin on the 
subject, even though an embolic agent specified for UFE was 
approved by the FDA in November. There are also indications that 
many gynecologists aren’t even mentioning UFE to patients as a 
treatment option - an omission that some observers view as a violation 
of informed consent (Clinical Management Guidelines for Obstetrician- 
Gynecologists, May 2000, No. 16). 
On the other hand, UFE is a relatively new procedure. So until 
recently, clinical studies of its performance have been inherently small 
and sometimes unflattering. 
"I think there is valid scientific caution on the part of gynecologists," 
said Dr. Evan Myers, an associate professor of obstetrics and 
gynecology at Duke University Medical Center in Durham, NC, and a 
leading public health expert on fibroids. 
"But there’s always a bit of a turf battle that goes on," Myers said. "This 
is not the first, and not the last time that a new specialty has come out 
with a procedure or treatment in an area that has traditionally been that 
of another specialty." 
The resistance among gynecologists has already spawned a mini¬ 
revolution in radiology practice, inspiring more interventionalists to 
obtain hospital admitting privileges or develop clinics so they can treat 
the many UFE patients who self-refer. 
"It has basically forced us into a situation of providing a full clinical 
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service," said Dr. J. Mark Ryan, an interventional radiologist at Duke. 
"We now have gone back to our roots of being real clinical doctors who 
do ward rounds." 
In a presentation at the 2003 Society of Interventional Radiology (SIR) 
meeting in Salt Lake City, Ryan described his department's relationship 
with the ob/gyns as "acrimonious." As a result, his team has developed 
and implemented their own post-UFE pain management protocol 
without any input from gynecological colleagues (Radiology, August 
2002, Vol.224:2, pp.610-613). 
"(UFE) allowed us to develop an office practice with consultations and 
see patients outside of the hospital, which we hadn’t done before," said 
Dr. Neal Joseph, director of the two-year-old South Florida Fibroid 
Center in Hollywood "Now, in addition to seeing several fibroid patients 
every office day, we’re seeing peripheral vascular patients, renal 
patients, oncologic patients, aortic stent graft patients - all for 
consultations." 
Encouraged by the success to date and the substantial upside potential 
of UFE, the interventional radiology community is working to win more 
hearts, minds, and patients. Major initiatives include research that will 
hopefully sway gynecologists or at least negate their objections, 
national information campaigns to educate physicians and the public 
about the procedure, and local direct-to-consumer marketing by 
individual practitioners and radiology groups. 
Quiet epidemic 
A major reason for the successful consumer marketing of UFE is that 
so many patients are suffering immensely from fibroid symptoms. 
These include pain and very heavy bleeding that can cause anemia 
and keep women from work and other activities Initial treatment 
generally involves oral contraceptives or non-steroidal painkillers, 
although these are often insufficient. 
Interestingly, although fibroids are by definition a problem of the 
childbearing years, removing the uterus is the most common surgical 
solution. Fewer than 40,000 myomectomies occur each year in the 
U.S., compared to the 150,000 or more hysterectomies performed 
annually for the treatment of fibroid symptoms. 
In fact, U S. hysterectomy rates have declined only a little over the last 
two decades, and remain three times higher than rates in Australia and 
western Europe, according to an analysis published last year in the 
American College of Obstetrics and Gynecology’s peer-reviewed 
journal (Qpstetrics & Gynecoiogy, February 2002, Vol. 99:2, pp. 229- 
234). 
"The drivers for innovation tend to be either industry or physician 
groups," noted gynecologist and researcher Myers. "Hysterectomy 
cures the problem, so there hasn’t been a huge demand, at least from 
physicians, for alternative treatments." 
At the same time, myomectomy has been far from definitive. Unlike 
UFE, which is designed to cut off the blood supply to all fibroids, 
surgeons confronted with multiple fibroids at myomectomy must 
choose which few to tackle. Interventional radiologists say that many of 
their UFE patients have previously undergone myomectomy. 
http://www.auntminnie.com/default.asp7Sec—sup&Sub—wom&Pag—dis&Itemld—58353&stm—... 2/7/04 
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"What we see very often is that the fibroids rapidly go back," says Dr 
Steven Janney Smith, director of interventional radiology at LaGrange 
Hospital near Chicago. "It almost seems like when you take fibroids out 
with myomectomy, you just make more room for the little fibroids." 
This pre-embolization, sagittal T1-weighted 
midline MR depicts an enlarged uterus with 
multiple fibroids highlighted by white arrows. 
The black arrow points out the uterus 
impinging anteriorly on the bladder neck. 
Image courtesy of Dr. Steven Janney Smith. 
Many myomectomy patients end up having a hysterectomy. But 
interventional radiologists suggest that gynecologists may have 
underestimated the number of patients who want to preserve their 
fertility, or who have a cultural or personal aversion to hysterectomy. 
"What I’ve heard many, many times is, ‘I just don’t want to lose my 
uterus. To me it would feel like a castration,’" Ryan said. 
The same patient six months after the UFE 
procedure. This sagittal, T1-weighted midline 
MR image shows a 50% decrease in the size 
of the uterus (white arrow). The fibroids have 
http://www.auntminnie.com/default.asp7Sec—sup&Sub-wom&Pag—dis&Itemld—58353&stm—... 2/7/04 
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low signal (black arrow), consistent with 
devascularization. The patient reported 
complete relief of symptoms. Image courtesy 
of Dr. Steven Janney Smith 
Patients are also self-referring for the other benefits of UFE, 
interventionalists said As with most interventional radiology 
procedures, UFE is less invasive than the surgical alternatives. A 
catheter is inserted into the femoral artery and is threaded to the 
uterine arteries, where embolizing particles of plastic or gelatin are 
released. Hospitalization is usually one night. 
After UFE most women can resume normal activity within a week, a 
shorter time than some myomectomy approaches and definitely shorter 
than the standard six-week recovery after hysterectomy. The shorter 
recovery time is appealing for working women and those with families. 
Physician shift 
Given the pokey evolution of gynecology’s fibroid treatments, it’s 
probably not surprising that gynecologists have been slow to even 
acknowledge the availability of UFE But change is occurring. 
After interventional radiologists at Yale University in New Haven, CT, 
began offering UFE in 1998, they started tracking gynecologists’ 
opinion of the procedure by asking patients about the advice they 
received. Among women who underwent UFE at Yale between 1998 
and mid-2000, only 10% had learned about the procedure from their 
gynecologists. 
Pre-UFE angiogram with 
catheter insertion. Contrast 
highlights fibroids. Image 
courtesy of Dr. Neal 
Joseph, Radiology 
Associates of Hollywood, 
FL. 
By mid-2000 to 2002, some 43% of the patients treated had heard 
about UFE from their gynecologists. But that increase doesn't placate 
the researcher who presented the latest findings to the Society of 
Interventional Radiology. 
"A majority of gynecologists still are not offering uterine fibroid 
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( en mbolization as an option," said Elizabeth K. Arleo, a third-year Yale 
medical student. "It’s disconcerting, because informed consent dictates 
that all possible treatment options should be mentioned." 
The post-UFE image 
shows arteries occluded for 
a reduction in blood flow to 
the fibroids. Image courtesy 
of Dr. Neal Joseph, 
Radiology Associates of 
Hollywood, FL. 
Financial self-interest is the driving issue, contends Yale 
interventionalist Dr. Michael Tal. "The obstetrics is not as lucrative and 
there's a lot of malpractice (insurance costs), so hysterectomy is one of 
the main sources of income for gynecologists." 
Whatever self-interest they may have, gynecologists are changing their 
stated position on UFE. Only 33% of the gynecologists described in 
the latest Yale survey were opposed to UFE when it was raised as a 
treatment option, compared to 76% two years earlier. 
Interestingly, gynecologists may take a financial hit if they oppose 
UFE The research also found that patients who underwent the 
procedure despite their gynecologist’s opposition were very unlikely to 
see that gynecologist again. 
Patients first 
The evolving opinions of gynecologists probably reflect their increasing 
familiarity with UFE, both from national and local sources, Tal said. 
There have been more journal articles and news reports, and Tal has 
spoken directly to gynecology groups about UFE. 
"Initially, the patients that you will get based on those presentations are 
the patients that nobody wants to operate on," Taj said, citing patients 
with HIV, hepatitis, obesity, and other comorbidities. Still, "every patient 
is a way to capitalize on building a relationship with that specific 
gynecologist." 
So with every case, Tal_sends the gynecologist copies of all pre- and 
post-procedure clinical notes. "The key thing in building a UFE 
practice, in my opinion, is to take responsibility for the patient before, 
during, and after the procedure, and, while doing this, maintain a 
positive and open communication with the gynecologist," he said. 
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Even if interventional radiologists have initially taken on new clinical 
responsibilities because gynecologists refused to work with them, 
continuing with this approach seems logical and appropriate. 
"A model where the gynecologist refers the patient to the IR - who then 
does the procedure and the gynecologist then handles all the problems 
afterward - isn’t going to be very attractive," said gynecologist Myers. 
Getting back to basics: Dr. Michael Tat steps out of the 
interventional suite to talk with a patient about her UFE options. 
Often a woman’s ob/gyn won’t even entertain the subject, so it 
may be up to the interventional radiologist to take over. Image 
courtesy of Dr. Michael Tal. 
Interventionalist Smith agreed: "Why should I make them admit the 
patient and do all this if I’m getting paid to do the procedure? It’s not 
fair to them." 
Total responsibility for the patient also empowers interventionalists to 
provide the kind of service that generates good buzz. 
"Making sure there are no stones left unturned, making sure that you 
are treating the patient for post-procedural pain adequately - basically 
making a good experience for patients," said Ryan. "I think that has 
been extremely important." 
Consumer marketing 
Attention to detail does more than generate word-of-mouth business, 
Ryan says. Women also share their experiences in Internet health chat 
rooms that spread the word much farther and wider. 
In fact, the Internet appears to be critical in enabling UFE to avoid the 
fate of other new procedures that challenged entrenched approaches. 
"Women find out information on the Internet and they know what they 
want," said Tal. "So the gynecologists have to, and do, adapt to that." 
Interventionalists also credit the Web sites developed for their practice 
groups with bringing in numerous self-referred patients. "Without it I 
don’t know how we would have ever gotten started, since right out of 
the box we were kind of viewed as a threat to the livelihood of 
http://www.auntminnie.com/default.asp?Sec-sup&Sub=rwom&Pag-dis&ItemId-58353&stm-... 2/7/04 
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gynecologists," said Smith. 
As a new marketing tool for doctors, the Internet also presents some 
headaches For instance, Smith was somewhat chagrined when the 
Web site developer he hired selected DrFibroid.com as the Internet 
address. "It sounds like I’m a used-car salesman," he complained. But 
Smith kept the name because at that point, he didn't know that he 
could choose another 
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The SIR advertising campaign, marketing UFE directly to 
patients, generated a significant increase in the number of 
procedures performed. Image courtesy of SIR. 
Other approaches that interventionalists have used to reach patients 
include speaking to women’s groups and inviting local television or 
newspaper reporters to see a procedure and interview previous 
patients. 
Then there is the marketing used by Joseph for the opening of the 
South Florida Fibroid Center in 2000. With help from a consultant who 
had promoted the University of Miami’s medical facilities, the fibroid 
center ran advertisements in major daily newspapers, on cable 
television, and on two radio stations whose listeners matched the 
demographics of fibroid patients. 
The two-month ad campaign worked so well -- especially the radio 
spots, which generated 90% of the self-referrals, Joseph said - that the 
center did it again a year later. 
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"We already had a good baseline, but it gave us another boost of 
patients," said Joseph, who also had anecdotal evidence that his 30- 
second descriptions of fibroid symptoms and treatment were being 
heard during drive time "I'd come to work and everybody was saying, 
"Oh, I heard you on the radio." 
The South Florida Fibroid Center is now handling 20 to 25 
embolizations a month. Joseph says that results have also influenced 
his colleagues at Radiology Associates ot Hoiiywooa. "It’s just got us 
into the habit of marketing ourselves and our practice both to 
physicians and to the public," he said. 
National news 
In addition to the marketing by individual UFE practitioners, SIR 
recently completed a yearlong public information campaign that 
included ads in Ebony magazine, the Journal of Family Practice and 
Annals of Internal Medicine, and dissemination of video and print press 
releases and public service announcements. 
The campaign generated significant increases in traffic to SIR’S call 
center and Web site: Phone inquiries went up from 45 to 200 per 
month, and hits on the Web site’s UFE "physician finder" went from 
25-33 per day to as high as 81 in one day. 
Demand for SIR’S information has slowed with the conclusion of its 
campaign, although the society continues to provide patient and 
physician "Grand Rounds" information both on its Web site and as 
handouts for use by its 3,000 members. 
The education effort has also been picked up by BioSphere Medical, a 
Rockland, MA, company that received FDA approval of its acrylic co¬ 
polymer embolizing beads in November. BioSphere is now advertising 
a toll-free hotline (1-877-ASK-4UFE) and Web site 
( www ASK4UFE) through the New York Times and the Wall Street 
Journal. 
But mass marketing doesn’t always fit comfortably with medicine. 
"The problem with any kind of direct-to-patient marketing (by 
physicians) is there’s no real oversight of the validity of claims," Myers 
said. "Historically, new innovations tend to get marketed very 
aggressively, and gynecologists have been guilty of that as well with 
various laparoscopic procedures." 
Judging UFE 
Interventional radiologists agree that their procedure should be 
validated through traditional scientific scrutiny, although many argue 
that the medical literature already makes an excellent case for UFE’s 
safety and efficacy. After all, embolization of the uterine arteries has 
been performed for more than 25 years to stem postpartum 
hemorrhage, with studies showing successful treatment and 
subsequent pregnancies among the patients. 
SIR recommends providing referring physicians with studies published 
in their specialty journals, such as the series of reports in Fertility and 
Sterility on the Ontario Uterine Fibroid Embolization Trial, a prospective 
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multicenter study of 555 UFE patients. 
Another popular citation is an article in Obstetrics and Gynecology by 
Dr. James Spies and colleagues at Georgetown University in 
Washington, DC. It reported on 400 consecutive patients who 
underwent embolization, with serious complications for only 1.25% and 
a 5% overall periprocedural morbidity rate (July 2001, Vol. 98:1, pp. 29- 
34). 
Other articles have reflected less favorably on UFE, including a UCLA 
study that found that women were more likely to need further invasive 
treatment after UFE than after myomectomy (Obsieirics and 
Gynecology, November 2002, Vol. 100:5, part 1, pp. 864-868). 
Thus, many UFE providers are participating in further research to 
confirm their perception of the procedure. Foremost among these is the 
FIBROID registry spearheaded by SIR’S Cardiovascular and 
Interventional Radiology Research and Education Foundation 
(CIRREF). This registry now includes data on more than 3,000 patients 
treated at dozens of sites around the world. 
In a talk at the 2003 SIR conference, Dr. Robert Worthington-Kirsch 
from the CIRREF FIBROID Registry Steering Committee shared the 
latest data on patient demographics and procedure techniques. Boston 
Scientific of Natick, MA, and Biosphere provided research funds for the 
multicenter registry. Both companies manufacture embolic 
microspheres used in UFE. 
This pre-UFE, sagittal FSE MR image depicts a large submucosal 
fibroid and several small intramural fibroids. Image courtesy of Dr. J. 
Mark Ryan. 
"As of August 31,2002, we have 2,605 cases logged," Worthington- 
Kirsch said. "Of those 2,605 patients, 2,471 have given consent for 
long-term follow-up, and 2,300 cases were available for analysis. 
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Registry enrollment closed after the first of January with somewhat 
over 13,000 patients enrolled. Data has been provided from 58 sites, 
52 in the U S., four in Canada, one in the U.K., and one in Hong Kong." 
The mean age of the women undergoing UFE was 43.4 with 
Caucasians and African-Americans making up the bulk of the patient 
population. Comorbidities included obesity, smoking hypertension, and 
diabetes In terms of reproductive history, just under half had never had 
a child, he said. 
"Just over half the patients were evaluated by MRI, and half the 
patients were evaluated by either transabdominal or transvaginal 
ultrasound. The mean uterine volume was just under 1,300 cc with a 
reasonable spread. Half the patients had one or two fibroids; about a 
quarter of the patients had five or more fibroids," Worthington-Kirsch 
said The majority of patients (85%) complained of menorrhagia. Other 
symptoms included bulk or pressure and pain. 
This sagittal FSE MR image, one-year post-UFE, shows a marked 
reduction in uterine volume and almost complete shrinkage of the 
submucosal fibroid, as well as a decrease in the size of intramural 
fibroids. Image courtesy of Dr. J. Mark Ryan. 
In terms of technique, the primary embolic agent used was calibrated 
microspheres in just under 75% of the patients, he reported. In just 
over half the patients, microcatheters were used with an average of 
about 1.2 catheters per case. 
"The mean procedure time was about 55 minutes; the mean 
fluoroscopy time was 16.3 minutes, and this agrees with other 
procedures of similar difficulty and complexity," Worthington-Kirsch 
said. "An average of 64 angiographic images were obtained The 
overall technical success was 98%, with both uterine arteries 
embolized. Just about everybody received (intravenous) conscious 
sedation during the procedure and then most received RCA (patient- 
controlled analgesia) narcotics afterward for pain management." The 
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average hospital stay was 1.4 days. 
The principal investigator for the FIBROID registry is Duke gynecologist 
and researcher Myers. He says the database will enable some good 
conclusions about the safety of UFE, as a start But it won’t 
necessarily enable comparisons with other fibroid treatments. 
Myers summarized the problem as lead author of a 2001 report by the 
U S. Agency for Healthcare Research and Quality on management of 
uterine fibroids: "In general, there was a remarkable lack of high-quality 
evidence supporting the effectiveness of most interventions for 
symptomatic fibroids." 
Still, winning over gynecologists will probably require radiologists to 
demonstrate their initiative as researchers as well as clinicians. "I think 
if there was good data that this was equivalent to myomectomy, it 
would be harder for there to be resistance," Myers said. 
Duke’s Ryan is among the interventional radiologists looking to do a 
head-to-head trial, assuming that gynecologists will participate after he 
publicly criticized their attitude toward UFE. 
"You know Osama bin Laden? Well, I came next on the list, pretty 
much," said Ryan of the reaction he received. "But things have 
evolved, and there’s been generation of mutual respect and greater 
appreciation of what we as interventional radiologists do." 
By 1 racie L. Thompson 
AuntMinnie.com contributing writer 
June 13,2003 
Additional reporting by Shalmali Pal. 
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